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ABSTRACT
Statistical Methods and Models for Modern Genetic Analysis
by
Matthew S. Zawistowski
Chair: Sebastian Zo¨llner
The Genome-Wide Association Study (GWAS) is the predominant tool to search for
genetic risk variants that contribute to complex human disease. Despite the large
number of GWAS findings, variants implicated by GWAS are themselves unlikely
to fully explain the heritability of many diseases. In this dissertation, we propose
statistical methods to augment GWAS and further our understanding of the genetic
causes of complex disease.
In the first project, we consider the challenges of a gene-environment analysis
performed as a follow-up to a significant initial GWAS result. It is known that effect
estimates based on the same data that showed the significant GWAS result suffer
from an upward bias called the “Winner’s Curse.” We show that the initial GWAS
testing strategy can induce bias in both follow-up hypothesis testing and estimation
for gene-environment interaction. We propose a novel bias-correction method based
on a partial likelihood Markov Chain Monte Carlo algorithm.
In the second project, we shift attention to rare genetic variants that have low
power of being detected by GWAS. We propose the Cumulative Minor Allele Test
(CMAT) to pool together multiple rare variants from the same gene and test for an
excessive burden of rare variants in either cases or controls. We show the CMAT
performs favorably across a range of study designs. Notably, the CMAT accommo-
dates probabilistic genotypes, extending applicability to low-coverage and imputed
sequence data. We use a simulation analysis to validate study designs that combine
sequenced and imputed samples as a means to improve power to detect rare risk
variants.
viii
Determining conditions that optimize imputation accuracy is important for suc-
cessful application. In the final project, we propose a coalescent model of genotype
imputation that allows fast, analytical estimates of imputation accuracy across com-
plex population genetic models. We use our model to compare the performance of
custom-made reference panels drawn from the same source population as imputation
targets to publicly available reference panels (i.e. 1000 Genomes Project) that may
differ in ancestry from the targets.
ix
CHAPTER I
Introduction
The identification of genetic variants that contribute to common complex disease is
an area of intense interest in the current field of human genetics. As such, substantial
research is devoted to the development of statistical methods to powerfully analyze
genetic data to detect risk variants. The population-based association study involves
testing for a statistically significant correlation between genotype and phenotype in a
set of independent samples and has emerged as the preeminent tool in complex disease
genetics [65]. The simplicity of the test allows any genetic variant that can be typed
in a large sample to be tested for association; no prior knowledge of the potential
genotype-phenotype relationship is required. Due to the millions of single nucleotide
polymorphisms (SNPs) cataloged across the human genome by the The HapMap [2]
and 1000 Genomes Projects [18] and decreasing genotyping costs, the entire genome is
now routinely scanned for risk variants in Genome-Wide Association Studies (GWAS)
[17]. To date, GWAS have identified more than four thousand genetic variants that
predispose for complex diseases ranging from diabetes to bipolar disorder to breast
cancer [25, 31, 69, 73].
Although risk variants identified by GWAS account for an appreciable fraction of
heritability for some phenotypes [80], it is more often the case that GWAS identified
risk variants explain only a small proportion of disease risk [42, 46]. Thus, despite
the overwhelming number of GWAS findings, our understanding of many complex
diseases remains incomplete. It is therefore necessary to consider conditions under
which GWAS are either unlikely to detect genetic risk variants or incorrectly charac-
terize their effect. GWAS experiments are often performed and interpreted under a
simple model of marginal genetic effects for individual risk variants. In reality, risk
for many complex diseases is likely the cumulative effect of genotypes at multiple risk
loci, with the potential for both epistatic effects and interactions with environmental
risk factors. The sheer number of GWAS findings with significant marginal effects
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supports extensive genetic and allelic heterogeneity. Interpreting GWAS results with
the simple marginal effect model ignores these more complicated relationships and
misrepresents the true genetic effect. So while GWAS are a powerful tool to initially
scan the genome, further analyses on implicated variants are required to fully under-
stand the genotype-phenotype relationship. Moreover, there is increasing theoretical
and empirical evidence that low frequency variants play a major role in complex dis-
ease [11, 58, 59]. GWAS are underpowered for testing such variants because they often
lack detectable marginal effects [34] and are therefore unlikely to detect individual
low frequency variants.
It is clear that novel statistical methods are required to complement the GWAS
and improve our understanding of complex human disease. In this dissertation, we
propose statistical methods that explore genotype-phenotype models beyond the con-
tribution of simple marginal effects. We consider an analysis for gene-environment
interaction performed as a follow-up to a significant GWAS result. We propose a sta-
tistical test for detecting sets of rare risk variants that affect the same gene. Finally,
we address strategies for imputing rare variants into large datasets.
Environment exposures are known to affect risk for many complex diseases. If
genetic variation also contributes to the risk of disease, it is possible that the effect of
the genetic risk variant can be modified by exposure to the environmental risk factors
(ERF) [33]. From a statistical perspective, the genetic risk variant and the ERF are
said to interact if the effect of each is dependent upon the other. This dependency
may or may not involve an actual biological interaction, but the relationship is impor-
tant nonetheless [10]. From a medical perspective, knowledge of the interaction can
improve risk prediction, treatment and preventative measures contingent upon ERF
exposure. Further, knowing the true form of the genotype-phenotype relationship
allows a more accurate assessment of the contribution of the variant to overall disease
prevalence.
Genetic risk variants that interact with an ERF can be identified by GWAS pro-
vided the marginal genetic effect of the locus is large enough. In the presence of a
gene-environment interaction, the marginal effect of a risk allele is the average of the
genetic effects over all levels of the ERF, weighted according to the frequency distri-
bution of the ERF. However, considering only the marginal effect of a risk variant
that interacts with an ERF can cloud the true genotype-phenotype relationship and
down play the role of the risk variant in disease etiology. For example, if a risk variant
has a large effect in the presence of a rare ERF but little to no effect in the absence
of the ERF, the marginal genetic effect of the risk variant will be small. Concluding
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that this variant has little effect on disease risk based on small marginal effect ignores
the substantial role it plays for a certain portion of the population. In addition, esti-
mates of marginal effect can be misleading if the frequency distribution of the ERF
in the dataset from which estimated are derived is not representative of the wider
population.
One of the major analysis challenges for gene-environment interactions is that
there is no definitive definition or model. In fact, there are likely to be a wide range of
genotype-environment-phenotype relations. As such, there is no consensus statistical
testing strategy for gene-environment interactions. Both case-control and case-only
population-based designs have been proposed. The case-control design directly tests
for differences in the effect size for the genetic variant conditional on exposure [10].
The case-only design is more powerful but requires independence between genotype
and exposure in the population. Type I error for a case-only analysis can be severely
inflated if the assumption is not met [55]. Recently, efforts have been made to com-
bine these strategies into a two-stage design [48]. However, it is often assumed that
both an ERF and a risk variant are known in advance for a disease and a “candidate-
interaction” analysis of the gene-environment pair can be performed. If a risk variant
is not known in advance, putative variants may first be identified through GWAS.
SNPs showing significance in the GWAS can then be subjected to a follow-up analysis
for interaction with an ERF. Provided exposure data was collected along with geno-
type data, such a follow-up analysis is trivial to perform but is prone to ascertainment
bias due to the requirement for a significant result in the initial GWAS test. Esti-
mates of genetic effect based on the same data that gives a significant GWAS result
are well-known to contain an upward bias known as the “Winner’s Curse.” [21, 72]
Since GWAS typically test for significant marginal effects, the Winner’s Curse has
been studied primarily for estimates of marginal genetic effect, with numerous cor-
rection methods proposed [79, 84, 85]. Although a similar bias is certain to exist on
estimates for a model of gene-environment interaction, it is not clear how the GWAS
requirement for a significant marginal effect will impact parameter estimates when a
different genotype-phenotype model is considered in the follow-up.
In chapter 2 of the dissertation, we examine the Winner’s Curse phenomenon in
studies of gene-environment interaction that are performed as a follow-up analysis
to a GWAS. We consider two distinct testing strategies that require a genome-wide
significant result in an initial GWAS-type test followed by formal testing and estima-
tion of gene-environment parameters. We compare the bias on parameter estimation
induced by each strategy and show that the choice of initial test can affect infer-
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ence for the follow-up analysis. To reduce bias, we propose an extension of the
ascertainment-corrected likelihood method introduced by Zo¨llner and Pritchard [85].
However, when applied to complicated models of gene-environment interaction, the
corrected likelihood cannot be written in analytical form making standard maximiza-
tion methods difficult to apply. Therefore we introduce a novel partial likelihood
Markov Chain Monte Carlo algorithm capable of computing bias-reduced estimates
from the intractable corrected likelihood function.
Another area we explore in this dissertation is the role of rare variation in com-
plex disease. Due in part to previous limitations in both the knowledge of existing
variation and genotyping technology, the search for the genetic causes of complex dis-
ease has previously focused primarily on common variation. The ambitious HapMap
Project aimed to catalog common variation in the human genome and to date has
identified 10 million common variants, mostly SNPs with minor allele frequency (maf)
≥ 5% [2]. Armed with the position and alleles for these SNPs, genotyping platforms
were built to allow large study samples to be assayed for hundreds of thousands to
millions of HapMap SNPs across the genome, making the GWAS possible. Despite
the number of SNPs that could be tested in a GWAS, the testable portion of the
genome was primarily limited to common SNPs available in the HapMap. With the
frequency spectrum for SNPs heavily skewed toward smaller frequencies, this leaves
rare variation as a vastly understudied portion of the human genome [18].
The Common Disease-Rare Variant model proposes that some of the missing her-
itability for complex diseases can be explained by rare variants with large effect sizes
[58, 59]. Under this model, the contribution of individual variants to population
prevalence is small but the combined effect of numerous rare variants can account for
an appreciable fraction of the prevalence. This model is feasible if risk variants are
subject to weak purifying selection and is supported by the fact that allele frequencies
for protein-altering mutations are more heavily skewed toward rare variants compared
to neutral variants [22]. Despite the obvious potential for rare variants in complex
disease genetics, technological limitations have hampered the ability to affordably
assay rare variants in large population-based samples. However, the advent of next
generation sequencing technology now provides the potential to detect all variation
in a genomic region, particularly novel rare variants [47]. The reality of observing all
genetic variation in large population-based samples will revolutionize our ability to
study the contribution of rare genetic variation to complex disease; however, it will
also bring numerous analytical challenges.
Individually testing each variant identified via sequencing in a large population-
4
based dataset is not a powerful strategy since power diminishes with decreasing allele
frequencies and the necessary multiple testing correction may be prohibitively strin-
gent [32]. Instead, statistical tests for excess accumulation of rare variation within a
genomic region in either cases or controls, so-called burden tests, have been shown
to be a more powerful alternative to single marker tests [34, 41]. Among the numer-
ous proposed burden tests, the common feature is to accumulate marginal evidence
for multiple rare variants within the same functional unit (e.g. a gene) into a single
statistic. The idea is that, individually, each marginal p-value may be insufficient to
declare an association but the p-value of their combined effect in a burden test may
reach statistical significance.
In chapter 3 of the dissertation, we introduce an intuitive and computationally
efficient burden statistic, the Cumulative Minor Allele Test (CMAT), to identify ge-
nomic regions containing rare variation that contribute to disease risk. We assess the
performance of the CMAT and other pooling methods on datasets simulated using
population genetic models to contain realistic levels of neutral variation. We consider
study designs ranging from exon-only to whole-gene analyses that contain non-coding
variants. For all study designs considered, the CMAT achieves comparable power to
previously proposed methods. A unique advantage of the CMAT is that it easily ex-
tends to probabilistic genotypes, allowing application to low-coverage sequencing and
imputation data. We illustrate that augmenting sequence data with imputed samples
is a practical method to increase power for rare variant studies. We also provide a
method to control for confounding variables such as population stratification. Finally,
we demonstrate that our method is capable of analyzing rare variants imputed into
existing GWAS datasets using external imputation templates. As proof of principle,
we performed a CMAT analysis of over 8 million SNPs imputed into the GAIN psoria-
sis dataset[49] using haplotypes from the 1000 Genomes Project [18]. In our analysis,
one gene, SKIV2L, maintained a significant test statistic after correcting for multiple
testing. The gene is located near the HLA region on chromosome 6 thought to harbor
multiple psoriasis susceptibility genes[49]. The CMAT statistic for SKIV2L contained
multiple rare variants (maf< 1%), none of which achieved genome-wide significance
in a single marker test, indicating that the CMAT can identify potentially interesting
genes that may otherwise be missed by single marker GWAS.
The previous CMAT analysis on the psoriasis data relied upon genotype imputa-
tion, the estimation of genotypes at untyped markers using known patterns of haplo-
type structure [37]. Imputation has already proven to be a powerful tool in modern
genetic studies by increasing the genomic coverage of GWAS and allowing for large-
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scale meta-analyses [74, 82]. As we show in the second chapter, imputation promises
to be as important in future genetic studies that involve sequencing technology to
target rare variation. In particular, power for rare variant burden tests of associa-
tion can be increased by augmenting sequencing datasets with imputed samples [81].
However, statistical power in genetic association studies is known to be affected by
imputation accuracy [28]. Thus, it is of interest to design imputation strategies that
optimize accuracy.
The imputation procedure involves a set of target samples in which genotypes are
to be imputed and a reference panel of phased haplotypes from which genotypes are
copied. Imputation accuracy is known to depend on several factors including reference
panel size, diversity, and genetic similarity to the imputation targets [2, 6, 27, 29].
Imputation is likely to be most accurate when the reference panel is drawn from
the same population as the target samples, or one that is closely related [2, 26, 39].
Haplotypes from the publicly available HapMap [2] and 1000 Genomes Projects [18]
currently serve as the imputation reference panel in most genetic studies despite
the fact that these haplotypes are usually not derived from the same population as
the imputation targets. Still, imputation accuracy is quite high using these panels,
particularly for common variants [2]. In the near future, however, next generation
sequencing will allow the creation of custom-made reference panels by sequencing a
subset of a large dataset to use as templates for imputing variation into the remain-
ing samples. Creation of these custom panels may be costly, so it is of interest to
determine the expected improvement in imputation accuracy for using custom-made
panels compared to the large, publicly available panels.
In chapter 4 of the dissertation, we propose a theoretical model of imputation
based on coalescent theory [30]. We use the coalescent to model the genealogical his-
tory of an imputation target haplotype and sets of reference haplotypes from potential
reference panels. We define a rule based on coalescence time to determine the refer-
ence haplotype that is expected to provide the best template for imputing untyped
alleles on the target haplotype. Based on this rule, we derive analytic equations to
quantify imputation accuracy for a given reference panel. The coalescent framework
facilitates complex population demographic models, allowing a range of imputation
study designs to be evaluated. Here, we use the model to compare imputation ac-
curacy between custom-made reference panels versus large, publicly available panels.
We find that custom panels from the same underlying population as the imputation
target, even when considerably smaller than competing publicly available panels from
closely related populations, are nearly always the optimal choice for imputation. The
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relative improvement in imputation accuracy gained by using a custom panel varies
according to both the divergence time between and the growth rates for the popu-
lations from which the panels are drawn. Improvement in imputation accuracy for
the custom panels increases as the divergence time between the two populations in-
creases. However, exponential growth in the populations from which the panels are
drawn attenuates the effect of the divergence, slightly reducing the improvement in
accuracy for custom panels. Thus, for populations experiencing exponential growth
and separated by small divergence times, imputation accuracy based on large, pub-
licly available panels can be comparable to moderately sized custom panels. Our
results suggest that future imputation-based genetic studies will benefit from custom
reference panels originating from the same population as the samples to be imputed.
However, a large publicly available reference panel (≥ 500 haplotypes) can provide
similar accuracy provided the reference haplotypes are not too distantly related to
the haplotypes to be imputed.
The projects in this dissertation are a next step in the search for the underlying ge-
netic causes of complex human disease. Our analysis method for gene-environment in-
teractions is designed to clarify genotype-phenotype associations previously detected
by GWAS. The CMAT is an alternative method to identify rare risk variants unlikely
to be detected by GWAS. Finally, our study of imputation strategies provides prac-
tical guidelines for designing powerful imputation-based genetic studies in the age of
next-generation sequencing.
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CHAPTER II
The Winner’s Curse in Studies of
Gene-Environment Interaction
2.1 Introduction
The Genome-wide association study (GWAS) is a powerful tool for identifying
genetic risk variants for complex human disease [65]. The basic design of the GWAS
is to individually test hundreds of thousands to millions of Single Nucleotide Poly-
morphisms (SNPs) across the genome in a set of unrelated samples for association
with a phenotype of interest. The primary goal is to identify putative risk variants
for the disease but a secondary goal is to estimate the effect size of any locus that
achieves statistical significance. Due to the large number of tests performed in a
GWAS, the same statistical test is generally applied to all SNPs in an automated
fashion. Here the emphasis is on the discovery of putative risk variants rather than
accurate modeling of the genotype-phenotype relation for any particular SNP. Thus,
the common choice for a GWAS is a simple test for significant marginal genetic ef-
fect since it is powerful to declare associations across a range of potential underlying
genetic models. Given that a SNP shows significance in the initial GWAS test, follow-
up analyses may attempt to replicate the initial finding as well as characterize and
quantify the true form of the association [8]. Although the GWAS may indicate a
significant marginal genetic effect, the follow-up analysis could test for a more compli-
cated genotype-phenotype relationship. For diseases with a known environmental risk
factor, an interesting follow-up analysis is to determine if any of the implicated genetic
risk factors interact with the environmental risk factor. Although the statistical in-
teraction does not necessarily reflect an actual biological interaction, the relationship
is important nonetheless and can be useful from a medical perspective to prescribe
treatment and preventative measures contingent upon environmental exposure [10].
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A major challenge to this type of follow-up analysis is to avoid ascertainment bias
induced by requiring a significant result in the initial GWAS test. Estimates of genetic
effect based on the same data that gave a significant GWAS result are well-known
to contain an upward bias known as the “Winner’s Curse” [21, 72]. The reason for
the bias is that effect size and significance level for a dataset are highly correlated.
Requiring a statistically significant test result restricts estimation to datasets with
larger effect estimates. The extent of the bias is directly related to the statistical
power of the initial test, with bias increasing as power for the initial test decreases.
The stringent significance threshold required for GWAS (p < 5x10−8) therefore makes
effect estimates from GWAS data especially prone to overestimation. The Winner’s
Curse phenomenon and its impact on GWAS parameter estimates is well-appreciated
in the field of statistical genetics [21, 72, 84]. It has been cited as a potential cause of
replication failure for true risk variants due to underestimation of replication sample
size requirements [46]. Characterizing and correcting for the Winner’s Curse effect in
GWAS is an active area of research [83, 79, 85]. The numerous statistical correction
methods that have been proposed typically assume that the effect estimate of interest
is the same effect that is tested for in the GWAS, for example, an odds ratio for
carriers of the risk allele in a logistic regression [83]. From the literature, it is clear
that conditioning on a statistically significant effect parameter will lead to upward
bias in estimates of that particular effect parameter. It is less clear how the Winner’s
Curse will affect parameter estimates in a follow-up analysis for a model that is
different from the one tested in the initial GWAS. In this dissertation chapter, we
examine the effect of the Winner’s Curse on parameter estimation and hypothesis
testing for models of gene-environment interaction performed as a follow-up analysis
to a significant GWAS result. We propose a general correction method that accounts
for the initial GWAS test and can estimate penetrance parameters for models that
differ from the initial test.
In the first part of the chapter, we focus on “naive” parameter estimation that
ignores the requirement for a significant GWAS result. We use simulation to de-
rive the sampling distributions for naive maximum likelihood estimates of a gene-
environment interaction model. We consider two testing strategies for the initial
GWAS: a chi-square test for marginal allelic association that ignores an environ-
mental risk factor, and a logistic regression that tests for either a significant genetic
main effect or a gene-environment interaction. We purposefully simulate data from
a gene-environment model that differs from the modeling assumptions of the two
GWAS tests. We show that requiring a significant GWAS result leads to a Win-
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ner’s Curse effect on parameters for the gene-environment model. However, the two
tests bias the follow-up analysis in different ways. Notably, the chi-square test for
marginal genetic effect inflates the false positive rate for a follow-up hypothesis test
of interaction when no interaction between the genotype and environmental exposure
exists. We conclude that the gene-environment follow-up study design requires an
ascertainment-correction method to allow valid analysis.
In the second part of the chapter, we propose a method to correct for the Win-
ner’s Curse effect observed in a follow-up analysis of gene-environment interaction.
To do so, we extend the likelihood-based correction method described by Zo¨llner
and Pritchard that conditions on a significant initial GWAS result [85]. It is shown
that the conditional likelihood function can be simplified to the ratio of the uncon-
ditional likelihood and the power of initial GWAS test. For their analysis, Zo¨llner
and Pritchard assumed that the power function in the denominator could be writ-
ten in a closed form equation. However, for many underlying disease models this
assumption is not realistic. For example, if the initial test is a logistic regression but
the underlying disease model does not follow the form of the regression, closed form
power functions do not exist. Though the conditional likelihood function is still valid,
without an analytic form for the denominator most standard maximization methods
are not applicable. Power can be estimated by simulation but this is computationally
prohibitive if the quantity needs to be repeatedly computed.
To obtain corrected estimates from the conditional likelihood function, we intro-
duce a novel Markov Chain Monte Carlo (MCMC) algorithm, the partial likelihood
MCMC. Our proposed algorithm is a modification of the MCMC without likelihood
algorithm described by Marjoram et al. for inference on likelihood functions that are
either impossible or computationally prohibitive to compute [45]. Movement in the
MCMC without likelihoods algorithm is determined in part by a rejection sampling
step that eliminates the need to evaluate the likelihood function. Instead, given a
proposed step for the chain, data is simulated from the likelihood function based
on the proposed parameter and the step is rejected if the simulated data does not
match the observed data. If the simulated data is comparable to the observed data,
a Metropolis-Hastings step involving only the proposal density (and the prior, if one
exists) is performed. Thus the MCMC without likelihoods can be used to derive the
sampling distribution (or posterior distribution) of parameters without the need to
ever evaluate a complicated likelihood function.
In the case of the conditional likelihood function of Zo¨llner and Pritchard, only
the denominator is computationally prohibitive and it is preferable to incorporate
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the computable numerator in parameter estimation. Thus, the partial likelihood
MCMC is specifically designed to account for the intractable denominator while also
including information from the numerator in the algorithm. Similar to the MCMC
without likelihood, we include simulation-rejection step in our algorithm. However,
we evaluate the tractable portion of the likelihood in a Metropolis-Hastings-like step.
The simulation-rejection step involves simulating data according to the unconditional
likelihood function, testing the data with the initial GWAS test and allowing a move
only if the dataset is statistically significant. Given the effect parameters for the
current state of the chain, the probability that a dataset drawn according to those
parameters is statistically significant in the GWAS test is precisely the statistical
power for those parameters. Thus, our simulation-rejection step follows directly from
the intractable portion of the conditional likelihood. The main idea behind the partial
likelihood MCMC is that the rejection sampling forces the chain to explore portions
of the parameter space containing low power for the GWAS test. Effect sizes for
these low-power parameters will generally be smaller and therefore reduce estimates
of effect.
We formally prove that the partial likelihood MCMC has as its stationary dis-
tribution the corrected likelihood function. In applying the algorithm, we produce a
random sample of quasi-independent realizations from the corrected likelihood func-
tion and use a summary statistic of the sample as corrected parameter estimates. We
show that for effect parameter values that have low or moderate power in the initial
GWAS, the corrected estimates reduce Winner’s Curse bias and provide more accu-
rate power estimates for a replication analysis. Parameter values that have high power
in the initial GWAS can actually be over-corrected resulting in an underestimate of
the effect.
2.2 Model
Let M denote a disease penetrance model for a biallelic locus and dichotomous
environmental risk factor (Table 2.1). Let g ∈ {0, 1, 2} be the number of risk alleles at
the locus and e ∈ {0, 1} an indicator for exposure to the environmental risk factor. Let
A and U indicate affected cases and unaffected controls for disease status, respectively.
To simplify notation, we define an ordering on the six genotype-exposure combinations
as follows. Let gei, 0 ≤ i ≤ 5, be the ith genotype-exposure category where i = 2g + e.
Then the model M is specified by a vector of penetrance values θ = {θ0, θ1, ..., θ5},
where θi = P (A|gei) ∈ [0, 1], and a frequency vector φ = {φ0, φ1, ..., φ5}, where
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φi = P (gei) ∈ [0, 1] and
∑5
i=0 φi = 1. Given θ and φ, the population disease
prevalence for M is defined to be F = φ′θ = ∑5i=0 P (A|gei) P (gei).
i Genotype Exposure Frequency φ Penetrance θ
2g + e g e P (gei) P (A|gei)
0 0 0 φ0 θ0
1 0 1 φ1 θ1
2 1 0 φ2 θ2
3 1 1 φ3 θ3
4 2 0 φ4 θ4
5 2 1 φ5 θ5
Table 2.1: Gene-environment penetrance model M
Given the penetrance model M, let D = {a0, a1, ..., a5, u0, u1, ..., u5} denote the
data configuration for a case-control dataset where ai and ui are the number of cases
and controls, respectively, in the ith genotype-exposure category. Then Na =
∑5
i=0 ai
is the total number of cases and Nu =
∑5
i=0 ui is the total number of controls in
the dataset. Assuming a retrospective case-control sampling design, the counts of
cases within the genotype-exposure categories {a0, a1, ..., a5} follows a multinomial
distribution with the probabilities for each genotype-exposure category defined by
P (gei | A,θ,φ) = P (A|gei)× P (gei|φ)
F
=
θi × φi
F
, (2.1)
Likewise, the genotype-exposure counts for controls {u0, u1, ..., u5} follow a multino-
mial distribution with sampling probabilities given by
P (gei | U,θ,φ) = P (U |gei)× P (gei|φ)
1− F =
(1− θi)× φi
1− F . (2.2)
Assuming independence between cases and controls, the probability of the full data
configuration D, conditional on the model M, is
P (D | θ,φ) ∝
5∏
i=0
P (gei|A,θ,φ)ai × P (gei|U,θ,φ)ui (2.3)
From an inference standpoint, if D is an observed random sample and our interest is
in estimating θ, then the likelihood function for θ conditional on D is
L(θ | D,φ, ) = P (D | θ,φ). (2.4)
12
Next we assume the data configuration D is collected as part of a GWAS and is
subjected to an association test at a genome-wide significance level. We assume that
penetrance parameters will be estimated from D only if D is statistically significant in
the initial GWAS test. Otherwise, D is not of interest and the penetrance parameters
are not estimated. In this case, the set of data configurations for which penetrance
parameters are estimated is not representative of the true underlying distribution of
all possible data configurations. Simply put, D is not a random sample from Eq.
(2.4) because it is required to have a significant GWAS result.
Following Zo¨llner and Pritchard [85], we derive the likelihood function for pene-
trance parameters θ conditional on the data configuration D being statistically sig-
nificant in the initial GWAS test. Let Sα denote that the dataset D is statistically
significant at level α for the initial test of association. Then the conditional likelihood
L(θ|D,Sα) that accounts for data D being significant in the initial test can be written
as
L(θ|D,φ, Sα) = P (D|Sα,θ,φ) = P (Sα|D,θ,φ) × P (D|θ,φ)
P (Sα|θ,φ) =
P (D|θ,φ)
P (Sα|θ,φ) (2.5)
where P (Sα|D,θ,θ) = 1 since we are restricting attention to datasets that are sta-
tistically significant. Thus, the conditional likelihood L(θ | D,φ, Sα) reduces to the
ratio of P (D|θ,φ), the unconditional likelihood of θ (eq. 2.4), and P (Sα|θ,φ), the
statistical power of the initial test at level α.
2.3 Statistical methods
2.3.1 Prevalence constraint
For simplicity, we focus on estimating θ from the data D and assume that φ and
F are fixed constants known from an independent source, for example a different data
set. Under the model M, fixing φ and F places a constraint on the parameter space
of θ since, by definition, F = φ′θ. For fixed values of F and φ, the hyper-plane given
by
ΘF,φ = {θ ∈ [0, 1]6|F = φ′θ} (2.6)
defines the set of θ values that satisfy the prevalence constraint. Since we assume
throughout that F and φ are known constants, estimation methods for the penetrance
parameter θ must be performed over the space ΘF,φ. Since φ is assumed constant, we
hereafter drop the φ term from the likelihood functions (eq. 2.4 and 2.5) to simplify
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notation. All methods described can be modified to include estimation of φ.
2.3.2 Naive estimate of θ
We assume that penetrance parameters θ are estimated only for data configura-
tions D that are statistically significant in the initial test of association. Given a
statistically significant data configuration D, we define a naive estimate of θ to be
any estimate that ignores the significance requirement and instead treats D as a true
random sample. Thus naive estimates of θ are based on the unconditional likelihood
function L(θ | D) that ignores the GWAS ascertainment (eq. 2.4). Here, we consider
naive maximum likelihood estimates (MLEs) of θ obtained by maximizing the un-
conditional likelihood function subject to the prevalence constraint (eq. 2.6). Thus,
naive MLEs of θ are defined as
θˆ = argmax
θ∈ΘF,φ
L(θ | D).
We describe a stochastic grid search algorithm to compute the naive MLE’s θˆ in the
Appendix (Section 2.7.1).
2.3.3 Corrected estimate of θ
We define corrected estimates of θ to be estimators based on the conditional likeli-
hood function (eq. 2.5) Obtaining estimates from the conditional likelihood function
using standard maximization methods is difficult because the term in the denomina-
tor, P (Sα|θ), cannot be written in analytical form for many testing scenarios. For
example, if logistic regression is used for the GWAS test, the non-central chi-square
distributed power function is valid only if the data follows the form of the regression
[70]. Given a penetrance vector θ, P (Sα|θ) can be estimated using Monte Carlo
simulation and a numerical method such as the grid search algorithm (Section 2.7.1)
can be used to maximize the conditional likelihood. This approach can be compu-
tationally prohibitive because it requires repeatedly estimating power for the initial
test.
2.3.4 Partial likelihood Markov Chain Monte Carlo
We introduce the partial likelihood Markov Chain Monte Carlo (MCMC) algo-
rithm to obtain estimates from the conditional likelihood L(θ|D,Sα). Below we give
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the steps for the partial likelihood MCMC algorithm and then prove that it converges
to the conditional likelihood L(θ|D,Sα).
Due to the prevalence constraint, the parameter space for θ is ΘF,φ. Let q :
ΘF,φ×ΘF,φ → [0, 1] be a valid probability density for proposing new points on ΘF,φ,
conditional on the current state of the chain. Then, assuming the chain is currently
at θ, let q(θ → θ∗) denote the probability of proposing a move to θ∗. The specific
proposal density we employed is described in detail below (2.3.5). Assuming a valid
proposal density q, the partial likelihood MCMC algorithm proceeds as follows:
Algorithm 1:
1. If currently at θi ∈ ΘF,φ, draw D∗ according to P (D | θi).
2. If D∗ is statistically significant at level α, draw θ∗ ∈ ΘF,φ
according to q(θi → θ∗).
Otherwise set θi+1 = θi and return to step 1.
3. Calculate h = h(θi,θ
∗) = min
{
1, P (D|θ
∗) q(θ∗→θi)
P (D|θi) q(θi→θ∗)
}
.
4. Set θi+1 = θ
∗ with probability h, otherwise set θi+1 = θi and return to step 1.
We next prove that the chain of vector penetrance values {θ1,θ2,θ3, ...} produced
by the partial likelihood MCMC has as its stationary distribution the desired condi-
tional likelihood function L(θ | D,Sα).
Theorem The stationary distribution of the partial likelihood MCMC is P (θ |
D,Sα).
Proof: By construction, r(θ → θ∗) = P (Sα|θ) q(θ → θ∗) h(θ,θ∗) is the transition
probability of the chain. It is sufficient to show that P (θ | D,Sα) and r satisfy the
detailed balance equation
P (θ | D,Sα) r(θ → θ∗) = P (θ∗ | D,Sα) r(θ∗ → θ).
Consider θ∗ 6= θ such that
P (D | θ∗) q(θ∗ → θ)
P (D | θ) q(θ → θ∗) ≤ 1.
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Then,
P (θ | D,Sα) r(θ → θ∗) = P (D | θ)
P (Sα | θ) P (Sα | θ) q(θ → θ
∗) h(θ,θ∗)
= P (D | θ) q(θ → θ∗) P (D | θ
∗) q(θ∗ → θ)
P (D | θ) q(θ → θ∗)
= P (D | θ∗) q(θ∗ → θ)
= P (D | θ∗) q(θ∗ → θ) P (Sα | θ
∗)
P (Sα | θ∗) h(θ
∗,θ)
=
P (D | θ∗)
P (Sα | θ∗) P (Sα | θ
∗) q(θ∗ → θ) h(θ∗,θ)
= P (θ∗ | D,Sα) r(θ∗ → θ).
Now assume P (D|θ
∗) q(θ∗→θ)
P (D|θ) q(θ→θ∗) > 1. Then h(θ,θ
∗) = 1 and similar steps show that the
equality holds.
The partial likelihood MCMC can be used to generate a random sample from
a general function that contains an intractable portion. The algorithm makes use
of the observed data by evaluating the tractable portion of the function in a stan-
dard Metropolis-Hastings step (step 3) yet accounts for the intractable portion using
a simulation-rejection sampling step (step 2). As presented, the partial likelihood
MCMC generates a chain of penetrance vectors that converges to L(θ|D,Sα) without
requiring the power function P (Sα|θ) to be repeatedly computed. The computational
requirements for the partial likelihood MCMC are: (1) given a penetrance vector θ,
we can simulate data configurations according to the unconditional sampling distri-
bution P (D|θ) (eq. 2.3) and (2) we can subject the simulated data set to the same
test used in the GWAS. Sampling data configurations using equation (2.3) is compu-
tationally straightforward since the unconditional likelihood is simply the product of
multinomial distributions.
A challenge in implementing the partial likelihood MCMC is that if the current
state of the chain is a set of penetrance parameters that have very low power it is
possible that a statistically significant dataset is never drawn and the chain remains
stuck at this parameter vector. To avoid this situation, we limit the number of times
that the simulation-rejection step is performed on the same parameter vector by
forcing a new vector to be proposed and performing a standard Metropolis-Hastings
step that includes the complete unconditional likelihood. That is, assume that say
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100 datasets have been simulated and rejected for the current vector θi. We then
propose a new vector θ∗ according to q(θi → θ∗) and compute
h(θi,θ
∗) = min
{
1,
P (D|θ∗) P (Sα|θi) q(θ∗ → θi)
P (D|θi) P (Sα|θ∗) q(θi → θ∗)
}
where P (Sα|θi) and P (Sα|θ∗) are estimated by simulation. We complete the Metropolis-
Hastings step by accepting the proposal with probability h(θi,θ
∗). We find that this
inclusion encourages the chain to move from areas with low power penetrance values.
Given the chain of penetrance values {θ1,θ2,θ3, ...} produced by the partial like-
lihood MCMC, we create a random sample of quasi-independent penetrance vec-
tors from the corrected likelihood L(θ|D,Sα) by removing the first B − 1 vectors
to allow the chain to reach its stationary distribution (burn-in) and then only re-
taining every T th vector to reduce correlation (thinning). Thus, from the full chain
{θ1,θ2,θ3, ...,θK}, we select the sub-chain {θB,θB+T ,θB+2T , ...,θB+kT} as the ran-
dom sample. Given this random sample, we estimate θi, 0 ≤ i ≤ 5, the penetrance
value for ith genotype-exposure category, with
θ¯i =
1
k + 1
k∑
j=0
θB+jT,i
where θB+jT,i is the penetrance value for the i
th genotype-exposure category in the
B+ jT th penetrance vector produced by the partial likelihood MCMC. Thus, we take
the marginal means for the six genotype-exposure categories from our random sample
as corrected estimates of θ and define
θ¯ = {θ¯0, θ¯1, ..., θ¯5}. (2.7)
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Since φ′θB+jT = F for each θB+jT in the random sample,
φ′θ¯ =
5∑
i=0
φiθ¯i
=
5∑
i=0
φi
1
k + 1
k∑
j=0
θB+jT,i
=
1
k + 1
k∑
j=0
5∑
i=0
φiθB+jT,i
=
1
k + 1
k∑
j=0
F
=F.
Thus θ¯ ∈ ΘF,φ and our corrected point estimate satisfies the prevalence constraint.
2.3.5 Proposal density q(θ → θ∗)
Here we derive a proposal density for the space ΘF,φ. Assume that the current
state of the chain is the vector θ. Let  > 0 be a fixed constant and let
∂(x,y) =
√∑
i
(xi − yi)2
denote Euclidean distance. We define PR(θ) = {θ∗ ∈ ΘF,φ | ∂(θ,θ∗) < }, the set
of valid penetrance vectors that satisfy the prevalence constraint and are within  of
θ, to be the proposal region about θ. In the following, we describe a computational
algorithm to sample uniformly from PR(θ) by first drawing a direction and then a
distance to define the proposal.
First, draw a random point p ∈ R6 such that F = φ′p. Note that the point p
lies on the extended plane defined by the prevalence constraint ΘF,φ, but need not
be a valid penetrance vector (i.e. 0 ≤ pi ≤ 1,∀i). Next compute the unit vector
d = θ−p
∂(θ,p)
. The vector d will indicate the proposal direction. To determine the
proposal magnitude, first let m = min{θ0, θ1, ..., θ5, 1 − θ0, 1 − θ1, ..., 1 − θ5} be the
minimum distance between the penetrance vector θ and the edge of the parameter
space ([0, 1]6). Then draw the step size δ from Uniform[0,min{m, }]. Note that δ
is allowed to be as large as  only if θ is more than  away from the boundaries.
Otherwise, δ is at most the minimum distance between θ and the boundary.
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Let θ∗ = θ + δd and note that θ∗ ∈ PR(θ) since ∂(θ,θ∗) = δ <  and
φ′θ∗ =φ′θ + δφ′
(
θ − p
∂(θ,p)
)
=F +
δ
∂(θ,p)
(φ′θ − φ′p)
=F.
because φ′θ = φ′p = F . Since both the directional vector d and the proposal
magnitude δ were uniformly chosen, θ∗ is a uniform random draw from the proposal
region PR(θ). It follows that the proposal density has the form
q(θ → θ∗) =
V (PR(θ))−1, θ
∗ ∈ PR(θ),
0, otherwise
(2.8)
where V (PR(θ)) is the volume of the proposal region PR(θ), which depends onm, the
minimum distance of θ to the boundary of the parameter space. If m ≥ , V (PR(θ))
is the volume of the intersection between the plane ΘF,φ and a six dimensional −ball
centered at θ. If m < , V (PR(θ)) is the the volume of the intersection of the plane
ΘF,φ and a six dimensional m − ball centered at θ. In either case, an analytical
computation of V (PR(θ)) is difficult.
However, since the proposal density q appears in the Metropolis-Hastings ratio
(Algorithm 1, step 3) as
q(θ∗ → θ)
q(θ → θ∗) =
V (PR(θ))
V (PR(θ∗))
, (2.9)
we need only compute the ratio of the two densities rather than the actual value of
each density. If the minimum distance between the boundary and both θ and θ∗ is
at least , then V (PR(θ)) = V (PR(θ∗)) and the ratio is one. If either or both of the
minimum distances is less than , we use rejection sampling to obtain a Monte Carlo
estimate of the ratio as follows.
Let Bθ, = {b ∈ R6 | φ′b = F, ∂(b,θ) ≤ }. Then Bθ, is a superset of PR(θ)
containing vectors less than  from θ that satisfy the prevalence constraint but are
not required to fulfill the [0, 1] boundaries for the individual vector components. Note
that if the minimum distance between θ and the [0, 1]6 boundary is greater than 
then Bθ, = PR(θ). Let V (Bθ,) be the volume of Bθ,. It is important to note
that V (Bθi,) = V (Bθj ,), ∀θi,θj ∈ ΘF,φ since the volume of the intersection between
the -ball and the extended ΘF,φ plane is the same regardless of where the -ball is
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centered. Then for any θ, we can estimate the ratio V (PR(θ))/V (Bθ,) by sampling
vectors from Bθ, and tallying the count that are also in PR(θ). Thus for θ,θ
∗ ∈ ΘF,φ,
we can estimate Eq. (2.9) in the Metropolis-Hasting ratio as follows
V (PR(θ))
V (PR(θ∗))
=
V (PR(θ))
V (Bθ,)
V (PR(θ∗))
V (Bθ∗,)
2.4 Simulation methods
In this section, we describe our simulation method to derive the sampling distri-
butions for naive estimates of θ that ignore the GWAS significance requirement and
corrected estimates based on the partial likelihood MCMC algorithm. Thus far we
have defined the penetrance vector θ and the frequency vector φ in as general terms
to allow versatility of the methods. However, we simulate datasets according to an
additive penetrance model of gene-environment interaction, denoted M+.
For simplicity, we assume a risk allele frequency of p with Hardy-Weinberg pro-
portions at the locus, an environmental exposure frequency of f and independence
between genotype and exposure status. This allows the elements of φ to be computed
as functions of p and f . For the penetrance vector θ, we assume a baseline penetrance
of m for unexposed individuals homozygous for the non-risk allele with additive ge-
netic (d) and environmental main effects (e) and an interaction (e′) within exposed
individuals homozygous for the risk allele. Parameters for the additive penetrance
model M+ are summarized in Table 2.2.
i Genotype Exposure Frequency φ Penetrance θ
2g + e g e P (gei) P (A|gei)
0 0 0 (1− p)2 × (1− f) m
1 0 1 (1− p)2 × f m+ e
2 1 0 2p(1− p)× (1− f) m+ d
3 1 1 2p(1− p)× f m+ d+ e
4 2 0 p2 × (1− f) m+ 2d
5 2 1 p2 × f m+ 2d+ e+ e′
Table 2.2: Additive model of gene-environment interaction M+. For simulations we
assume risk allele frequency p, exposure frequency f with independence
between genotypes and exposure. The penetrance vector is parameter-
ized with additive genetic (d) and environmental main effects (e) and an
interaction term (e′).
We construct the sampling distribution for naive MLEs of θ, conditional on a
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significant GWAS result, using the following algorithm:
Algorithm 2:
1. For fixed values of θ and φ, simulate a data configuration D according toM+.
2. Test D for association at genome-wide significance α.
If D is significant, go to step 3; otherwise discard D and return to step 1.
3. Assuming F and φ are known, compute the naive estimator θˆ.
4. Return to step 1.
By design, the algorithm computes MLEs only for datasets from P (D | Sα,θ),
the conditional likelihood for θ (Eq. 2.5). However, the naive MLEs are computed
based on the unconditional likelihood L(θ | D) (Eq. 2.4). For our simulations,
we generate data according to the additive penetrance model M+ (Table 2.2) and
then computed naive MLEs for that model. That is, θˆ = {mˆ, eˆ, dˆ, eˆ′}. We use a
stochastic grid search algorithm to perform the constrained maximization (Appendix
2.7.1) but other methods may also be used. For simulations with no interaction effect
(e′ = 0), we performed a follow-up hypothesis test for evidence of a gene-environment
interaction. Formally, we tested the null hypothesis e′ = 0 using a likelihood ratio
test after re-computing naive MLEs with e′ fixed at zero.
We consider two testing strategies for the initial GWAS (Algorithm 2, step 2).
The first is a 2x2 Allelic Chi-Square Test that collapses the data D into risk al-
lele counts for cases and controls, ignoring the environmental exposure, and testing
strictly for a marginal allelic effect at the locus. The second testing strategy employs
a logistic regression that includes main effects for risk allele carriers (βG1 ) and homozy-
gotes (βG2 ), environmental exposure (β
E) and interaction parameters (βGE1 , β
GE
2 ) for
each genotype-exposure level. We use a Likelihood Ratio Test in the logistic re-
gression framework to test for either significant main genetic or interaction effects
(H0 : β
G
1 = β
G
2 = β
GE
1 = β
GE
2 = 0) while controlling for the main effects of the
exposure. Whereas the first testing strategy ignores the environmental exposure in
the initial GWAS, the second strategy explicitly models and tests for potential inter-
actions in the initial GWAS. Note that neither of these tests assume the true additive
form of the penetrance vector is known. The testing strategies are described in more
detail in the Appendix (2.7.2).
To compute sampling distributions for the corrected estimates θ¯ we use the same
steps in Algorithm 2, except at step 3 we use the partial likelihood MCMC to compute
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θ¯. However, to demonstrate the model-free aspect of the algorithm, we compute the
corrected estimates θ¯ assuming the general six-parameter penetrance modelM (Table
2.1) .
2.5 Results
2.5.1 Sampling distributions for naive estimates θˆ
We simulated datasets for an additive penetrance model of gene-environment in-
teraction (Table 2.2) and used Algorithm 2 to we generate the sampling distribution
for parameter MLEs of the model, conditional on first showing significance in an ini-
tial GWAS. We considered three scenarios of gene-environment interaction: (1) true
genetic and interaction effects (d > 0, e′ > 0), (2) true interaction but no genetic ef-
fect (d = 0, e′ > 0), and (3) true genetic but no interaction effect (d > 0, e′ = 0). The
initial association tests were performed at α = 10−8. Simulated datasets contained
Na = 1000 cases and Nu = 1000 controls. For each scenario, we show results for three
sets of penetrance parameters that provide low, medium and high power for the two
initial GWAS tests considered. We report sampling distributions for maximum like-
lihood parameter estimates of the additive penetrance modelM+ and the estimated
odds ratios for increase in risk associated with an additional copy of the risk allele.
2.5.1.1 True genetic and interaction effects (d > 0, e′ > 0)
At high power, the parameter estimates for genetic effect (d) and interaction
effect (e′) are unbiased for both initial testing strategies. As power decreases to the
medium level, the estimates of d and e′ begin to show an upward bias for both tests
(figs. 2.1 & 2.2). The extent of the bias increases when power is low. The baseline
(m) and exposure (e) estimates are underestimated at medium and low power due
to the prevalence constraint on the penetrance parameters. Note that for a fixed set
of parameter values, the logistic regression provides a more powerful test resulting
in less extreme bias. Although bias appears subtle for parameter values, it leads to
more substantial bias in the odds ratios.
2.5.1.2 True interaction but no genetic effect (d = 0, e′ > 0)
Next we consider a model with a true interaction effect but lacking a main genetic
effect. Here the two tests differ with respect to bias on MLEs for the genetic and
interaction parameters (figs. 2.3 & 2.4). Initial screening with both the chi-square test
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and the logistic regression result in similar bias on point estimates of the interaction
parameter e′. However, the chi-square test also induces a clear bias on the genetic
term while the logistic regression remains unbiased for that parameter. This is the
result of the logistic regression explicitly modeling both main genetic and interaction
effects whereas the allelic chi-square test merges the signal of the two. As a result,
odds ratios based on samples significant in the chi-square test suffer from a larger
bias, especially at low power.
2.5.1.3 True genetic but no interaction effect (d > 0, e′ = 0)
As in the previous scenario, the chi-square test induces a bias on both the genetic
and interaction terms (fig. 2.5). The estimate of genetic effect is biased for the logistic
regression but the interaction estimate is unbiased, again the result of explicitly sepa-
rating the two effects in the initial model (fig. 2.6). For datasets showing a significant
result in the initial genome scan, we performed a follow-up test for a gene-environment
interaction. We formally tested the null hypothesis of no interaction (H0 : e
′ = 0)
using a likelihood ratio statistic and comparing it to the chi-square distribution with
one degree of freedom. The QQ plots of observed versus expected p-values for the
interaction test show that, at low power, the logistic regression induces only a slight
departure from the expected null distribution (fig. 2.7). However, initial screening
with the chi-square test results in a more extreme departure from the null. For the
parameter values with the lowest power considered, the follow-up test with expected
α level of 5% has actual Type I Error of 7% when screened with the logistic regression
method and 14% for the chi-square test. Thus, the initial test used to identify the
locus in a genome scan effects the α-level of future hypothesis testing on the same
data.
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Figure 2.1: Naive MLEs conditional on genome-wide significance in the allelic chi-
square test (d > 0, e′ > 0). The top graph shows the distribution of
parameter estimates at three power levels for the initial test. True pa-
rameter values are indicated by the red lines. At medium and low power,
the estimates of d and e’ have an upward bias. The bottom graph shows
estimated odds ratios for each additional copy of the risk allele. Subtle
biases in the individual parameters leads to a large bias in the odds ratios.
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Figure 2.2: Naive MLEs conditional on genome-wide significance in the logistic re-
gression (d > 0, e′ > 0). As with the Allelic Chi-Square Test, the logistic
regression framework results in bias for both d and e′. However, logistic
regression is more powerful and leads to less extreme bias.
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Figure 2.3: Naive MLEs conditional on genome-wide significance in the allelic chi-
square test (d = 0, e′ > 0). Initial screening with the chi-square test
results in a bias on both d and e′.
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Figure 2.4: Naive MLEs conditional on genome-wide significance in the logistic re-
gression (d = 0, e′ > 0). Like the Allelic Chi-Square Test, the logistic
regression framework leads results in biased estimates of the true signal
source e′. Unlike the Allelic Chi-Square Test, estimates for d remain
unbiased under the logistic regression.
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Figure 2.5: Naive MLEs conditional on genome-wide significance in the allelic chi-
square test (d > 0, e′ = 0). Again, the chi-square test induces a bias
on parameter estimates for both d and e′. Combined with fig. 2.3, this
implies that regardless of the true source of signal, the screening with
the allelic chi-square test that ignores environmental exposure results in
biased estimates for both genetic main effects and interaction.
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Figure 2.6: Naive MLEs conditional on genome-wide significance in the logistic re-
gression (d > 0, e′ = 0). Conditioning on the logistic regression result
biased estimates of the true signal parameter d and unbiased estimates
for e′. Thus, the logistic regression testing framework results in biased
estimates of true effect parameters but unbiased estimates for null value
parameters.
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Figure 2.7: QQ plots for type I error in follow-up tests of gene-environment interac-
tion. Initial GWAS testing with the allelic chi-square test (left column)
results in an elevated Type I error for a follow-up test of interaction when
no interaction exists. Type I error remains controlled when the logistic
regression (right column) is used in the initial test.
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2.5.2 Corrected estimates θ¯
In this section we present results for the partial likelihood MCMC algorithm and
demonstrate that the corrected estimates θ¯ reduce bias on parameters for the gene-
environment interaction model. Following Algorithm 2, simulated datasets according
to the additive penetrance model of gene-environment interaction M+ (Table 2.2)
and computed θ¯ for datasets significant in the initial GWAS test. To demonstrate
the model-free aspect of the partial likelihood MCMC, we assumed the additive form
of the gene-environment model was not known during estimation. That is, we used
the partial likelihood MCMC to estimate penetrance parameters for the general six-
parameter modelM (Table 2.1). The results presented in this section are based on the
additive penetrance parameters (m, e, d, e′) = (0.12, 0.12, 0.02, 0.02), corresponding to
θ = {0.12, 0.24, 0.14, 0.26, 0.16, 0.30}. We used the logistic regression framework at
α = 5 × 10−8 for the initial GWAS test. Datasets contained Na = 10, 000 cases and
Nu = 10, 000 controls
It is difficult to directly show that the partial likelihood converges to the condi-
tional likelihood function L(θ|D,Sα) (Eq. 2.5). Instead we show that each component
of the six-dimensional estimator θ¯ converges. Our results are based on running the
chain for a total of ten million iterations, removing the first one million for burn-in
and thinning the chain by keeping only every thousandth state of the chain. This re-
sulted in a total of nine-thousand penetrance vectors in the quasi-independent random
sample used to estimate θ¯.
Figure (2.8) shows the results for ten independent runs of the partial likelihood
MCMC on the same dataset. Each plot in the figure shows the running estimate
for one of the values θ¯i computed at each step in the random sample produced by
the chain. Each of the colored lines in the plots indicates an independent run of
the MCMC and shows that the estimate for θ¯ converges for each of the ten runs.
Further, for each θ¯i, the estimates from the ten independent runs converge to a
common value, indicating consistent estimates of the parameters between runs. We
note that the penetrance estimates for the first four genotype-exposure combinations
converge faster than the estimates for θ¯4 and θ¯5 because of large case-control counts
in those categories due to higher allele and exposure frequencies (p = 0.1, f = 0.4).
The estimates for θ¯4 and θ¯5 show slight variability when the chain is stopped at 10
million iterations, however, when we allowed the chain to continue to 50 million total
iterations the individual estimates continued to converge toward a common value.
We found that the slight variability in estimates for θ¯4 and θ¯5 obtained at 10 million
iterations of the chain did not affect the results in the subsequent analysis.
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Next we present results comparing the corrected parameter estimates to naive
estimates at a range of power values for the initial GWAS (Figure 2.9). For each
power level, we computed naive and corrected estimates for 100 datasets statistically
significant in the initial GWAS test and report the mean for each estimator. To
obtain different power levels, we kept the penetrance parameters fixed and adjusted
the allele and exposure frequencies. The corrected estimates are generated using the
partial likelihood MCMC algorithm. Here, the naive estimates are computed using a
standard MCMC algorithm to allow comparison.
When power is low (20%), each component of the naive estimator is biased. Pene-
trance for non-risk allele homozygotes (θ0 and θ1) are underestimated and penetrance
for carries of the risk allele (θ2 . . . θ5) are overestimated, indicating an upward bias
of genetic effect. Corrected estimates based on the partial likelihood MCMC reduce,
but do not eliminate, the bias for each penetrance value. At moderate power (50%),
the naive estimates show a bias for each parameter though slightly reduced from the
low power setting. The corrected estimates again reduce this bias for each of the
individual penetrance parameters and for several, the bias is nearly zero.
For the parameter setting with high power (80%), the ascertainment effect on the
naive estimates is considerable reduced and they approach the true parameter values.
The naive estimates that still show a noticeable bias at high power (θ1, θ3 and θ4)
are nearly perfectly estimated by the corrected estimates. However, the corrected
estimates actually over-correct the remaining penetrance values.
The multidimensionality of the general six-parameter penetrance vector has the
advantage that it removes assumptions on the underlying gene-environment model.
However, the generality of the model also makes it difficult to fully appreciate the
significance of bias on parameter estimates. We provide an interpretation for the
bias by computing the estimated power for a replication study based on both the
naive and corrected estimates derived in the previous result. That is, for each set
of parameter estimates we computed the power for the logistic regression that was
applied in the initial GWAS testing. Figure (2.10) shows the estimates of power for
a replication analysis at the low, moderate and high power parameter settings. For
comparison we also computed replication power based on true random samples, that
is, datasets that were not required to show significance in the logistic regression and
do not contain an ascertainment effect. The large spread on these estimates show the
inherent variability in estimation for the six-parameter model and subsequent power
calculations.
At the low power setting, the replication power for uncorrected estimates is sub-
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stantially biased, with mean replication power nearly triple the true power value.
Replication power based on the corrected estimates substantially reduces the bias
although the mean is still nearly double the true value. At moderate power, uncor-
rected estimates again show a clear bias in estimates of replication power. Here, the
corrected estimates provide a nearly identical result to the estimates derived without
ascertainment. This corresponds to the result in Figure (2.9) that shows at moderate
power (50%), the correction algorithm has eliminated nearly all ascertainment bias on
individual parameter estimates. Finally, at the high power setting, the uncorrected
estimates provide replication power estimates similar to the estimates with no ascer-
tainment. The median of the distribution for replication power based on corrected
estimates is the true power. However, the distribution for corrected estimates is more
heavily skewed toward low estimates than either the no ascertainment or uncorrected
estimates. This reflects the slight over-correction that was observed for some of the
individual parameter estimates (Fig 2.9). In summary, the subtle bias in uncorrected
estimates of penetrance parameters can lead to substantial overestimation of power
for a replication study. The corrected estimates reduce this bias and produce esti-
mates of replication power that more closely resemble estimates derived from true
random samples.
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Figure 2.10: Power for a replication analysis based naive and corrected estimates.
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2.6 Discussion
The detection of gene-environment interactions will improve our understanding
of human complex disease, however, testing strategies for interactions require care
to avoid potential bias in the analysis. In this chapter, we considered an analysis of
gene-environment interaction as a follow-up to a significant GWAS result. We showed
that naive parameter estimates of both the main genetic and interaction effects that
ignore the ascertainment effect of requiring the significance result show an upward
bias. This result is consistent with the standard Winner’s Curse phenomenon that
is known to bias estimates of marginal genetic effects following a significant GWAS
hits.
We considered two testing strategies for the initial GWAS, the first was a test
for significant marginal genetic effects that ignored the environmental exposure, and
the second testing for either significant main genetic effects or an interaction between
genotype and exposure. We found that the follow-up analysis for interaction is af-
fected differently by the two tests. Parameter estimates for true genetic or interaction
effects have an upward bias for both tests, the classical Winner’s Curse. However, the
test for marginal genetic effect also overestimates genetic and interaction effect when
there is no actual effect for these parameters. As a result, the marginal effect test that
did not initially model potential gene-environment interactions had a substantially
inflated type I error in the follow-up hypothesis test for interaction. Alternatively, the
test that did initially model an interaction maintained the appropriate type I error.
Corrected estimates can be obtained through a likelihood function that conditions
on the significant GWAS result. The denominator of this likelihood is the power func-
tion for the GWAS test which, for most disease models and statistical tests, cannot
be expressed analytically. Thus we introduced a new type of MCMC algorithm, a
partial likelihood MCMC, to compute estimates from the conditional likelihood func-
tion. The partial likelihood MCMC accounts for this intractable denominator with
a simulation-rejection step and makes use of the observed data through a standard
Metropolis-Hastings step that contains the tractable portion of the likelihood. We
applied the partial likelihood MCMC algorithm to data simulated under our additive
penetrance model of gene-environment interaction. The estimates derived using the
partial likelihood MCMC show a decrease in ascertainment bias compared to naive
estimates and provide a more accurate estimates of power for follow-up testing.
In this chapter we considered a follow-up test for gene-environment interaction,
but our results can be extended to other analyses that first screens for a significant
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GWAS result. An obvious example is follow-up tests for gene-gene interactions. As
with gene-environment interactions, initially testing all possible SNPs for interaction
is not a powerful approach. Instead,a n initial GWAS could identify SNPs with sig-
nificant marginal effect and these SNPs could then further scrutinized for interactions
with other SNPs. Our results indicate the potential for increased false positives in
such an analysis if the initial GWAS test is not properly accounted for. An advan-
tages of our partial likelihood MCMC algorithm is that it can be applied to any type
of follow-up testing, including the gene-gene example describe here. The initial test,
whatever the form, can be accounted for in the simulation-rejection step. And be-
cause we do not require explicit model assumptions the for penetrance parameters, the
partial likelihood MCMC algorithm can be applied to any type of underlying model
structure. This is particularly appealing since the true form of gene-environment and
gene-gene interactions are often unknown.
In our application of the partial likelihood MCMC, we generated model-free esti-
mates for the penetrance parameters of the six genotype-exposure categories. How-
ever, it may be of interest to test the plausibility of a specific interaction model
while still controlling for the GWAS ascertainment effect. Due to the versatility of
the algorithm, it is possible to incorporate hypothesis testing into the partial likeli-
hood MCMC framework. Corrected parameter estimates for the “saturated” general
model would first be computed, as we have done here. Then ascertainment-corrected
estimates for parameters of a specific model of interest, for example our additive pen-
etrance model would be computed. The fit of the more specific model can be assessed
using a likelihood ratio test if the models are nested and Akaike information criterion
(AIC) [1] or similar comparison of fit if the models are not nested. Of course, for
both of these methods, the conditional likelihood function must be evaluated at the
parameter estimates. Given that parameter estimates for the general and specific
models, evaluation of the numerator is straightforward because it is simply the un-
conditional likelihood function. The denominator, statistical power for the parameter
estimates in the initial GWAS test, can be estimated using Monte Carlo simulation.
Then, for both the general and specific model, the corrected likelihood value can be
computed as the ratio of the uncorrected likelihood and the power estimate. This
testing framework allows interaction models that are not easily incorporated into a
regression framework, the most common format for initial GWAS tests, to be properly
analyzed.
The partial likelihood MCMC produces a random sample of penetrance vectors
from the corrected likelihood. Without corresponding likelihood values for the vectors,
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we based our corrected point estimates on a summary statistic from the sample. In our
gene-environment model, each point in the sample was actually a six-dimensional pen-
etrance vector, meaning that the choice for corrected estimates is not straightforward.
We chose to use the marginal mean for each penetrance value as corrected estimates
due to computational simplicity and because the six marginal means are guaranteed
to satisfy the prevalence constraint. In actuality, the MLE for the corrected likelihood
is the six-dimensional mode of the random sample but the multidimensionality and
continuous scale of the space make this value difficult to compute. It is likely that the
correction provided by the partial likelihood MCMC can be improved by choosing a
corrected estimate that is guaranteed to be closer to the true mode of the corrected
likelihood.
Gene-environment interactions are a promising model to explain complex human
disease. However, when performed as a follow-up analysis to a GWAS experiment,
care must be taken to avoid biased results. In this chapter, we have demonstrated the
GWAS ascertainment effect on gene-environment analysis. To reduce bias, we intro-
duced a flexible partial likelihood MCMC algorithm to compute parameter estimates
from a likelihood function that conditions on the initial significant result.
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2.7 Appendix
2.7.1 Stochastic grid search algorithm
We first describe a two-step, space-search algorithm used to compute MLEs of
θ under the additive penetrance model (table 2.2) for the uncorrected likelihood
function (eq. 2.4). We assume the true values of population prevalence F and fre-
quencies φ are known. Fixing both F and φ places a constraint on possible values
of θ (Eq. 2.6). In the additive penetrance model, given F and θ, ΘF,φ = {θ ∈
R4 | ∑5i=0 P (A|gei) P (gei) = F} defines the subspace of penetrance parameter val-
ues that satisfy the prevalence constraint. The first step in the space-search algo-
rithm is a coarse search over the domain ΘF,φ to identify the general region of the
MLEs. To do this, we randomly chose vectors θ∗ = (θ∗1, . . . ,θ
∗
C) ∈ ΘF,φ with uni-
form probability and computed the likelihood of the data D for each vector θ∗i . Let
θˆ∗ = argmaxθ∗ L(θ | D) be the penetrance vector that maximizes the likelihood
function in the coarse search.
Next we implemented a local random-walk to fine-search the region of θˆ∗ to de-
termine precise MLEs. At the ith step in the fine search, a new parameter vector θi
is proposed by perturbing three of the parameters from θi−1 = (mi−1, di−1, ei−1, e′i−1)
by a value less than  > 0 and solving for the fourth value subject to the prevalence
constraint. We accepted the proposed step only if it increased the likelihood of the
data D. We reduced  at each iteration. The parameter set θˆ = (mˆ, dˆ, eˆ, eˆ′) at the
conclusion of the fine search was declared the naive MLE for θ given data D.
2.7.2 Initial genome-wide association testing strategies
We considered two testing strategies for the initial genome-level scan. First, we
ignore the information on exposure status and test exclusively for a marginal allelic
association using a standard allelic χ2 test. Let ag =
∑2
g=1
∑1
e=0 g × a2g+e be the
number of putative risk alleles observed in cases and ug =
∑2
g=1
∑1
e=0 g × u2g+e be
the same quantity in controls. We compute the Pearson χ2 statistic
χ2Pear =
(Na +Nu) {ag(2Nu − ug)− ug(2Na − ag)}2
2(ag + ug)(2Na + 2Nu − ag − ug)(Na)(Nu)
and determine significance by comparing to the theoretical χ2 distribution with one
degree of freedom.
For the second testing strategy we use logistic regression to simultaneously test
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for either main genetic or interaction effects while controlling for exposure status. We
fit the saturated logistic regression model
logit [P (A|g, e)] = α + eβE + 1{g=1}βG1 + 1{g=2}βG2 + e1{g=1}βGE1 + e1{g=2}βGE2
This is the most general logistic model and contains main effect parameters for risk
allele genotypes (βG1 , β
G
2 ) and environmental exposure (β
E) plus interaction parame-
ters (βGE1 , β
GE
1 ) for each genotype-exposure level. We test the null hypothesis of no
main genetic or interaction effects (H0 : β
G
1 = β
G
2 = β
GE
1 = β
GE
2 = 0) by fitting the
reduced model
logit(P (A|g, e)) = α + eβE
and comparing the fits using a Likelihood Ratio Test with 4 degrees of freedom.
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CHAPTER III
Extending Rare Variant Testing Strategies:
Analysis of Non-Coding Sequence and Imputed
Genotypes
3.1 Introduction
The Genome-Wide Association Study (GWAS) is a powerful tool for analyzing
common variation across the human genome[65]. In recent years, GWAS have iden-
tified risk alleles for a wide range of complex human diseases[25]. However, most of
these alleles provide only small to moderate increases in risk and contribute little
to the overall heritability of the disease[42]. Since it is unlikely that the remaining
heritability can be completely explained by undetected common variants with even
lower effects[20], heritable factors besides common variation must contribute to com-
plex diseases. The Common Disease-Rare Variant Hypothesis proposes that some of
the missing heritability can be explained by low frequency variants with larger effect
sizes[58, 59]. Under this model, the contribution of individual variants to population
prevalence is small but the combined effect of numerous rare variants can account for
an appreciable fraction of the prevalence. This model is feasible if risk variants are
subject to weak purifying selection and is supported by the fact that allele frequen-
cies for protein-altering mutations are more heavily skewed toward rare variants than
those for neutral variants[22].
Previously, technological limitations hampered the ability to affordably assay and
test rare variants in large population-based samples. However, recent advances in
next generation sequencing technology now provide the potential to detect all poly-
morphisms in a genomic region[47]. Thus rare variants can be tested directly rather
than relying on indirect LD-based methods. Already, candidate region resequencing
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has discovered numerous rare variants contributing to phenotypic variation and com-
plex disease in humans. Resequencing of coding regions and consensus splice sites in
NPC1L1 and PCSK9 has successfully identified multiple rare non-synonymous mu-
tations collectively associated with variation in sterol absorption and plasma levels of
LDL-C[11, 12].
Individually testing each variant identified by resequencing is not a powerful strat-
egy since it requires stringent multiple testing correction and power diminishes with
decreasing allele frequencies[32]. To avoid these issues, several statistical methods
have been proposed that instead pool together multiple rare variants from the same
gene and jointly test them for association[11, 34, 41, 56]. The recent literature has
addressed two related question in rare variant testing: first, the question of how to
effectively combine multiple rare variants in a gene into a single test and second, how
to weight variants based on some prior assumption about the likelihood of functional-
ity. Cohen et al. performed a pooled analysis of rare variants in NPC1L1, identifying
non-synonymous variants observed only in cases or only in controls and comparing
the distributions of cases and controls carrying these variants with a Fisher Exact
Test[11]. Li and Leal proposed the Combined Multivariate and Collapsing method
that pools variants below a specified minor allele frequency (maf) then dichotomizes
individuals dependent on whether they carry a variant allele at one of the pooled
sites[34]. A multivariate statistic is used to jointly analyze the set of pooled variants
together with more common variants in the region.
Madsen and Browning introduced two features in the Weighted Sum Statistic
(WSS)[41]. First, the WSS accumulates rare variant counts within the same gene for
each individual rather than collapsing on them. Second, it introduced a weighting
term to emphasize alleles with low minor allele frequency in controls. The result
is a quantitative genetic score for each individual that is more informative than a
qualitative score, especially for individuals harboring more than one rare allele in
the region. The scores for all samples are ordered and the WSS is computed as
the sum of ranks for cases. Significance is determined by permuting affection status
and re-ranking. The ranking protects against outliers but becomes computationally
expensive for large sample sizes.
Price et al. [56] showed that the power gain of weights based on minor allele
frequency is dependent on the relation between risk allele frequency and likely effect
size which in turn is dependent on selection strength. The weights used by Madsen
and Browning, for example, correspond to strong purifying selection. If this model
is correct, the WSS provides a significant power gain over the previous methods.
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To generate a test that is powerful under multiple evolutionary models, Price et
al proposed a variable maf threshold approach. For a given frequency threshold,
a likelihood ratio statistic is computed to compare summed minor allele counts for
variants below the maf threshold for cases and controls. The likelihood ratio statistic
is maximized across a range of frequency thresholds to adapt the statistic to the
underlying model of selection.
All pooling statistics are subject to variant misspecification, that is, potential
inclusion of neutral variants or exclusion of risk variants. Study designs to date
have opted to minimize inclusion of neutral variants by limiting analysis to non-
synonymous coding variants of candidate genes[32]. The power of this strategy de-
pends on the cumulative effect of rare risk variants that are exonic. While coding
variants are most likely to be functional, they account for only a tiny fraction of vari-
ation in the genome. Numerous pieces of evidence indicate that non-coding variants
play an extensive role in disease etiology. 88% of trait associated variants identi-
fied by GWAS have occurred outside of known coding regions[25]. Large portions of
non-coding regions in the human genome are subject to negative selection indicating
a functional purpose to the sequence[3]. In addition, non-coding risk variants have
already been verified for numerous diseases[19, 23, 54]. Resequencing non-coding in-
tronic and regulatory regions may enable detection of these more elusive risk variants
but also presents new technical and analytical challenges to rare variant analysis. In
particular, non-coding sequence contains substantially more neutral variation than
coding regions.
Existing pooling methods have not been carefully assessed under a paradigm where
many risk variants reside outside exons. Instead, these methods have only been con-
sidered for fairly optimal testing conditions assuming few variants per gene, most of
which are causative[34, 41]. Moreover, previously published pooling methods assume
high-quality rare variant genotypes that are only available through deep-coverage se-
quencing. Exon-only studies can attain high quality genotype calls because sequenc-
ing is limited to relatively small regions. Generating high quality sequence data of
larger genomic regions (including whole-genome sequencing) is still expensive, limit-
ing the number of samples that can be sequenced at deep-coverage for a given study.
Instead, cost effective strategies such as low-coverage sequencing[18] and genotype
imputation[37] will be used to produce sample sizes large enough to powerfully an-
alyze rare variants. Genotype calls from these methods are less precise than deep
sequencing, generating probabilistic rather than exact genotypes. Thus tests applied
to whole-gene sequence data containing both coding and non-coding regions must
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accept probabilistic genotypes and be robust to potentially high inclusion rates for
neutral variants.
In this article, we consider a simple pooling statistic, the Cumulative Minor Allele
Test (CMAT), and show that it is easily extended to accommodate practical analysis
considerations such as qualitative covariates and probabilistic genotypes. The CMAT
is closely related to the tests described in Madsen and Browning[41] and Price et al.
[56] in that it aggregates allele counts rather than collapsing on them. Like these
methods, the CMAT jointly analyzes sets of variants in the same gene that would
otherwise be missed by a standard single marker analysis. Since power for single
marker tests is dependent on study sample size and risk allele frequency, the CMAT
is computed on variants with maf below a preset threshold. In this paper we especially
focus on markers with maf < 5% and hereafter refer to these as rare variants.
The CMAT statistic is computed by summing rare allele counts for sites predicted
to be functionally relevant separately for cases and controls. Our test statistic is anal-
ogous to the single marker allelic χ2 statistic typically used to test for allele frequency
difference between cases and controls. Significance is determined by permutation to
account for correlation between pooled variants.
We compare the power of several pooling methods on case-control sequencing
datasets simulated using population genetic models designed to mimic the overall level
of diversity seen in European HapMap samples. We create a disease model of allelic
heterogeneity by placing multiple rare risk variants in the population. The effect size
for each risk variant is determined by allele frequency to ensure low power for a single
marker test. Since our datasets contain realistic levels of neutral variation we can
consider the effect of variant misspecification, both inclusion of neutral variants and
exclusion of causal variants, in study designs ranging from exon-only to whole-gene
analysis. We show that, dependent on the proportion of non-coding risk variants,
whole gene designs may be more powerful that exon-only designs even if they include
a large number of neutral variants.
The form of the CMAT statistic conveniently allows for categorical covariates and
probabilistic genotypes. These extensions allow rare variant analysis for datasets
containing imputed genotypes or low-coverage sequence data as well as common con-
founding variables such as population stratification. We demonstrate the importance
of these extensions by analyzing two previously unconsidered rare variant study de-
signs. First, we simulate rare variant datasets containing spurious associations created
by population stratification. Ignoring the stratification leads to an elevated Type I
Error rate while controlling for it with the covariate form of the CMAT maintains the
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desired α-level.
Second, we present a study design consisting of both sequenced and imputed
samples. We assume the sequenced samples are used to identify novel rare variants
in a region of interest and then serve as templates to impute genotypes for these
variants into the remaining (non-sequenced) samples. While carefully accounting
for the uncertainty involved in imputing rare variants, we simulate datasets for this
study design and analyze them with the CMAT. We show that using imputation to
increase sample size of a sequencing dataset can substantially improve power. Hence
we predict that imputation will provide a powerful cost-saving strategy for future
resequencing studies. Moreover, our results suggest that existing resources such as
the 1000 Genomes Project can be used to reanalyze existing GWAS datasets by
imputing rare variants and performing tests such as the CMAT.
Finally, we illustrate the possibility of reanalyzing GWAS datasets without re-
sequencing samples. As a proof of principle, we imputed over 8 million SNPs into
the GAIN psoriasis GWAS dataset using CEU haplotypes from the 1000 Genomes
Project. This dataset had previously been augmented with genotypes imputed from
HapMap haplotypes and analyzed with a single marker association test[49]. That
analysis identified numerous common risk loci that were subsequently replicated, in-
cluding several variants in the HLA region on chromosome 6. We reanalyzed 3000
genes with at least 2 rare variants (maf≤ 5%) using the CMAT. One gene maintained
a significant test statistic after correcting for multiple testing, SKIV2L, located on
chromosome 6 near the HLA region.
3.2 Methods
In the following, we develop notation for exact and probabilistic genotype calls
then introduce the CMAT along with three alternative rare variant tests. Following
that, we describe our algorithm to simulate case-control sequencing data based on
population genetic models. Finally, we provide details for our application of the
CMAT to the GAIN Psoriasis dataset.
3.2.1 Data structure
We assume a dataset of NA cases and NU controls. Let xij ∈ {0, 1, 2} be the
true number of minor alleles at the jth variant site in the ith case. Let yij be the
same value for the ith control. We consider two possible types of genotype calls in
the data: exact calls, discrete values from {0, 1, 2} giving the observed minor allele
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count, and probabilistic calls consisting of a posterior probability mass function P (·)
giving the likelihood for each possible minor allele count. Exact genotypes reflect high
confidence calls possible in deep coverage sequencing data whereas the probabilistic
calls represent the uncertainty in low coverage sequencing and imputation. In the
dataset, we define the observed value for the jth variant site in the ith case to be
Xij =
xij, for exact genotype calls∑2
n=0 nP (xij = n), for probabilistic genotype calls.
That is, we assume the true minor allele count is observed if an exact call is made,
otherwise we observe the expected minor allele count based on the posterior proba-
bility distribution. Similarly, we define Yij for the j
th variant site in the ith control,
replacing xij with yij.
3.2.2 Cumulative minor allele test
We assume the genetic data are partitioned into a collection of discrete testing
units, genomic regions to be individually tested for association with disease suscepti-
bility. The most natural choice for a testing unit is a single gene but highly conserved
non-genic regions or pathways containing multiple genes are also suitable. Assume
F > 1 variants in the testing unit, each with a weighting factor wj ≥ 0, (j = 1, . . . F ).
A variant can be filtered out of the analysis by setting the respective weight to zero
or its presence emphasized by assigning a large weight. For this paper, wj is a simple
indicator function to identify variants included in the analysis (described in more
detail later). Note that a testing unit containing only a single variant with positive
weight is equivalent to a single marker test on that variant.
We first describe application of the CMAT to a dataset containing exact genotype
calls for all NA cases and all NU controls. Let mA =
∑NA
i=1
∑F
j=1wjXij and mU =∑NU
i=1
∑F
j=1 wjYij be the weighted minor allele counts across all sites in the testing
unit for cases and controls respectively. Then MA =
∑NA
i=1
∑F
j=1wj(2 − Xij) and
MU =
∑NU
i=1
∑F
j=1 wj(2−Yij) are therefore the weighted major allele counts across all
sites for cases and controls respectively. We define the CMAT statistic ΣCMAT to be
ΣCMAT =
NA +NU
2NANU
∑
j wj
× (mAMU −mUMA)
2
(mA +mU)(MA +MU)
. (3.1)
The statistic ΣCMAT is derived from the standard Pearson χ
2 statistic for testing in-
dependence between allele frequency and disease status in a single marker association
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test. However ΣCMAT does not have an asymptotic χ
2 distribution as independent
counts are required for the asymptotic properties to be valid. Since we sum over
multiple sites in a testing unit, some of which may be in LD with each other, the
counts are not independent. Instead, we determine statistical significance of ΣCMAT
by permuting affection status while holding the genetic data fixed. For each per-
muted realization, ΣCMAT is recomputed and the p-value is defined as the proportion
of permutations with a test statistic greater than or equal to the observed statistic.
In the presence of qualitative covariate data on potential confounders, the weighted
allele counts are computed separately within each covariate level and the form of
ΣCMAT is changed to a Cochran-Mantel-Haenszel-like statistic. Assume a qualitative
covariate c = 1, . . . , C. Using similar notation, we define the observed value for the
jth variant site in the ith case of the cth covariate class to be
Xijc =
xijc, for exact genotype calls∑2
n=0 nP (xijc = n), for probabilistic genotype calls.
Similarly, we define Yijc for the j
th variant site in the ith control of the cth covari-
ate class, replacing xijc with yijc. Assume NA,c cases and NU,c controls within the
cth covariate class and Nc = NA,c + NU,c. Weighted allele counts are then com-
puted within each covariate class separately. Let mA,c =
∑NA,c
i=1
∑F
j=1wjXijc and
mU,c =
∑NU ,c
i=1
∑F
j=1 wjYijc be the weighted minor allele counts across all sites in
the testing unit for cases and controls in the cth covariate class, respectively. Then
MA,c =
∑NA,c
i=1
∑F
j=1wj(2−Xijc) and MU,c=
∑NU ,c
i=1
∑F
j=1wj(2−Yijc) are therefore the
weighted major allele counts across sites for cases and controls of the cth covariate
class respectively. We define the covCMAT statistic ΣcovCMAT to be
ΣcovCMAT =
[∑
cmA,c − NA,c(mA,c+mU,c)Nc
]2
∑
c
NA,cNU,c(mA,c+mU,c)(MA,c+MU,c)
2N3c
∑
j wj
(3.2)
Statistical significance is determined by permuting case-control status while keep-
ing the genetic and covariate data fixed. Eq. (3.2) resembles the Cochran-Mantel-
Haenszel χ2 statistic and simplifies to Eq. (3.1) when C = 1.
We now consider a dataset containing NAseq cases and N
U
seq controls with exact
genotype calls and NA − NAseq cases and NU − NUseq controls with probabilistic calls.
Computation of ΣCMAT (Eq. 3.1) remains the same except expected minor allele
counts replace exact counts for imputed samples. Significance is again determined
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by permuting affection status. However, to account for the difference in quality
between the two data types, affection status must be shuﬄed separately for exact and
probabilistic calls. That is, for all permutations, the number of cases and controls
with exact genotype counts must remain constant. Failure to modify the permutation
method in this manner can affect Type I error, especially for unbalanced designs
(NAseq 6= NUseq).
3.2.3 Alternative rare variant methods
We compared the performance of the CMAT to three alternative rare variant
methods. First, we implemented the collapsing method described in Li and Leal[34]
comparing the distribution of cases carrying at least one rare variant to that of controls
carrying at least one rare variant. Let the indicator variable Xi denote whether the
ith case carries at least one rare variant at a site of interest as follows
Xi =
1, wjXij > 0 for any 1 ≤ j ≤ F0, otherwise.
Yi is analogously defined to indicate controls carrying at least one rare variant. Then
X =
∑NA
i=1Xi and Y =
∑NU
i=1 Yi are, respectively, the number of cases and controls
carrying at least one rare variant. The Pearson χ2 statistic,
χ2COLL =
(NA +NU)× (XNU − Y NA)2
NANU(X + Y )(NA +NU −X − Y )
tests the null hypothesis that cases and controls are equally likely to be carriers of a
rare variant. χ2COLL has an asymptotic χ
2 distribution with one degree of freedom.
Next, we considered a private allele test similar to the method used by Cohen et
al[11], comparing the number of rare variants unique to either cases or controls. For
this test we require an equal number of cases and controls (NA = NU). A site is defined
to be private if it is polymorphic in either cases or controls but monomorphic in the
other group. The minor allele at a private site is called a private allele. For example,
the minor allele at the jth site is private to cases if
∑NA
i=1Xij > 0 but
∑NU
i=1 Yij = 0.
Under the null hypothesis, rare variants are not associated with disease risk and
private alleles are therefore equally likely to occur in cases and controls. This is
tested formally using a χ2 test in the following manner: Let npriv be the total number
of private alleles in the dataset and nA and nU the number of private alleles unique
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to cases and controls respectively (npriv = nA + nU). Define
χ2PRIV =
(nA − npriv2 )2 + (nU − npriv2 )2
npriv
2
Under the null distribution of no association, χ2PRIV is asymptotically χ
2 distributed
with one degree of freedom. As with the CMAT and collapsing test, the private allele
test considers only variants with positive weighting terms.
Finally, we implemented the Weighted Sum Statistic as described by Madsen and
Browning[41]. For the ith individual in the dataset, we compute a genetic score de-
fined as γi =
∑F
j=1 wjXij. The genetic scores for all samples in the dataset (cases
and controls combined) are sorted and the sum of ranks of genetic scores for cases,
x =
∑
i∈cases rank(γi), is computed. Statistical significance of x is determined by per-
mutation. Madsen and Browning recommend upweighting rare variants by defining
weighting terms according to minor allele frequency in controls. We do not directly
consider the question of how to weight rare variants in this paper. Therefore, we
apply a simple uniform weighting scheme to all tests. However, for comparative pur-
poses, we include application of the WSS and CMAT using the weights defined in
Madsen and Browning (Supplementary Figure 3.7). The three alternative methods
have been formally defined only for exact genotypes, thus we limit power comparisons
to datasets containing only exact genotype calls.
3.2.4 Simulations
3.2.4.1 Deep sequence datasets
We simulated deep sequence datasets containing exact genotype calls for an equal
number N of cases and controls. We first created a population of ten-thousand
∼ 100kb haplotypes using the coalescent simulator cosi with parameters chosen to
reflect characteristics seen in the European HapMap samples[67]. Let ntot be the
total number of polymorphic sites among the ten-thousand population haplotypes.
Denote the allele at the jth site on the ith haplotype as Aij where Aij = 0 if the
major allele is present and Aij = 1 if the minor allele is present (i = 1, . . . , 10, 000
and j = 1, . . . , ntot). We fixed a maximum allele frequency pmax for risk alleles and
randomly chose k sites with maf< pmax to be causative. Let cj = 1 if the j
th variant
site is selected to be causative and cj = 0 if it is neutral.
For each risk variant, we assigned an effect size that ensured a single marker asso-
ciation test would have low probability of being statistically significant. Specifically,
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we computed the relative risk γp necessary for a risk variant with maf= p to have 10%
power in a one degree of freedom χ2 test of 1000 cases and 1000 controls performed
at α = 10−5 (Figure 1). As a result, rarer variants are assigned larger relative risks,
although we capped relative risks for variants with maf< 10−3 at 6. Assuming the
maf for the jth variant is p, we set the relative risk at that site RRj = γ
cj
p .
Assuming a multiplicative effect between causative variants, the penetrance φi for
haplotype i is,
φi =
√
b×
∏
j|Aij=1
RRj
where b is the risk for an individual with wildtype (non-risk) alleles at all causative
sites and is set to ensure the population prevalence remains fixed at a desired level.
Diploid cases and controls were then sampled by randomly drawing two haplotypes
conditional on disease status using Bayes’ Theorem. The probability that the ith and
jth haplotypes are chosen for a case, for example, is
Pr(hi, hj|case) = Pr(case|hi, hj)× Pr(hi)× Pr(hj)
Pr(case)
=
φi × φj
10, 0002 × Pr(case) .
assuming that unconditionally each of the ten-thousand population haplotypes are
equally likely to be selected. We treat the unconditional probability of being a case
(population prevalence) as a fixed parameter in our simulations.
Following the construction of a dataset, we mimicked a bioinformatic annota-
tion process to determine the set of variants predicted to be functional and therefore
included in the analysis. Each observed variant was randomly labeled as either ‘in-
cluded’ or ‘excluded’ from the analysis conditional on whether it was causative or
neutral. Define pc to be the probability that a causative variant is predicted to be
functional and therefore included in the analysis. Likewise, pn is the same probability
for neutral variants. Then, letting Ij be an indicator for inclusion in the analysis, the
jth variant is included with probability
Pr(Ij = 1) =
pc, cj = 1pn, cj = 0.
The values pc and pn were treated as parameters to simulate study designs with
alternative inclusion thresholds. Using the functional annotations, we defined the
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weighting terms used in our simulations
wj =
Ij, mafj ≤ β0, mafj > β. (3.3)
This weighting scheme therefore acted as a filter to retain variants with both maf≤ β
and predicted to be functional in the annotation step.
Figure 3.1: Relation between minor allele frequency and relative risk in our disease
model. The relative risk is chosen to ensure that a single marker test of
1, 000 cases and 1, 000 controls performed at α = 10−5 on a risk variant
with the specified maf has a maximum power of 10%. Relative Risks for
variants with maf< 10−3 were truncated to 6.
3.2.4.2 Imputation datasets
Next, we created datasets containing exact genotypes for Nseq cases and controls
assumed sequenced at deep coverage and probabilistic genotypes for an additional N−
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Nseq imputed cases and controls. Thus, in contrast to our deep sequence simulations
where we assumed deep sequence data for all samples, here we assumed deep sequence
data for only a fraction of the total sample size. It was computationally infeasible to
phase and impute genotypes for each simulated dataset, therefore we drew haplotypes
for N cases and controls using the previously described method and replaced the
true minor allele counts with expected minor allele counts for the imputed portion
of the sample. Expected minor allele counts were drawn from empirical sampling
distributions created using independent imputation runs (see Appendix). Individual
draws were made conditional on the true minor allele count at the locus to be imputed
and the number of times the minor allele at that site was observed in the sequenced
samples. We created separate empirical distributions for Nseq = 100, 200 and 400.
Only sites polymorphic among the sequenced samples were eligible for inclusion in
the analysis. Singletons in the sequenced samples cannot be accurately phased and
are therefore imputed. Hence, the minor allele must be observed at least twice in the
sequenced samples to be imputed.
3.2.5 Stratified datasets
To demonstrate the covariate form of the CMAT statistic we simulated datasets
containing population stratification. To do so, we used cosi to simulate sets of hap-
lotypes that reflect variation observed in European and African populations[67]. We
drew datasets containing N cases and N controls under the null hypothesis of no
risk variants (k = 0), however we preferentially chose haplotypes from the African
population to be cases. For each sample in a dataset, we first chose a population of
origin for the sample. We let p be the probability that a control is derived from the
African population and p+δ, (δ > 0), to be the probability that a case is derived from
the African population. Controls and cases are therefore drawn from the European
population with probability 1− p and 1− p− δ, respectively. Once population origin
is determined, we randomly selected two haplotypes from the appropriate population
to create a diploid sample. We analyzed each simulated dataset with both the CMAT
and the covCMAT, controlling for population of origin in the latter. When applying
the covCMAT, we assumed that the true population of origin was known for each
sample.
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3.2.6 Simulation settings
We fixed the population disease prevalence at 1% throughout the simulations.
Under our disease model, increasing the number of causative sites k while holding
prevalence constant increases the proportion of disease prevalence explained by vari-
ation at the locus. We focused our analysis on risk alleles with maf≤ 5% by setting
parameters pmax and β to 0.05. However we repeated our analysis restricting risk
variants to maf≤ 1% and report those results as well. However, since causative sites
were chosen at random and the allele frequency spectrum was heavily shifted to-
ward extremely low frequencies, approximately 95% of risk alleles in our simulations
have frequency < 1% even for simulations with pmax = 0.05. We estimated power
for each test at different parameter settings as the proportion of simulated datasets
with statistically significant p-values (based on a minimum of at least 1000 simulated
datasets). We report power at a critical level of α = 0.01 assuming the sequenced
region contains several genes to be tested.
3.2.7 GWAS application
We imputed 8.2 million autosomal SNPs into the GAIN Psoriasis dataset using
112 CEU haplotypes from the August 2009 release of the 1000 Genomes Project
as reference. We filtered the imputed SNPs, removing all variants with very low
estimated imputation accuracy (Rˆ2 < 0.3). We annotated SNPs discovered in the
1000 Genomes Pilot One Project using a custom Perl script. The tool reports for
each SNP the gene locus (if available) and the predicted protein effect, based on a set
of curated transcripts from Refseq and Genbank. We included SNPs annotated as
missense, nonsense, splice-site or UTR in our analysis. We filtered out variants with
maf> 5% and pooled the remaining variants together by genes. That is, we used the
following weighting strategy
wj =
1, mafj ≤ 0.05 and annotated as missense, nonsense, splice-site or UTR0, otherwise.
3.3 Results
3.3.1 Deep coverage sequencing datasets
To evaluate the performance of the CMAT, we used coalescent simulations to gen-
erate realistic case-control sequence data for a 100kb region of interest, representing
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the exons, introns and surrounding regulatory regions for a large gene. A dataset of
N = 1000 cases and controls drawn from a population with k = 15 rare (maf≤ 5%)
causative sites contained, on average, S = 1565 segregating variable sites with a mean
pairwise sequence difference pi = 0.00114. Of the observed sites, 1272 had maf≤ 5%
and we observed 12.4 of the 15 risk alleles. A larger dataset with N = 2000 cases and
controls contained an average of 1556 polymorphic sites with frequency < 5% and
14.1 of the 15 risk alleles. Larger sample sizes therefore increase both the number of
risk alleles observed in the sample as well as the number of neutral variants.
We mimicked functional filtering by analyzing only a subset of the variants ob-
served in a dataset. Conditional on being observed, causative variants were ‘predicted’
to be functional and therefore included in the analysis with probability pc; neutral
variants were included with probability pn. Since few of the observed variants are ac-
tually causative, pn is approximately the overall proportion of rare variants included
in the analysis while pc can be thought of as the success rate for including causal
variants.
We determined practical values for pc and pn by investigating the distribution of
functional annotations for genic SNPs in the dbSNP database[71]. Of genic SNPs
with at least one annotation, approximately 1.6% were denoted as non-synonymous
coding or splicing variants (nonsense, missense, frameshift or altered splice-site), 1%
were synonymous coding variants, 2.7% occurred in the UTR and 5.3% outside the
transcribed region of the gene. Intronic SNPs accounted for the remaining class
of variants. Thus, an overall inclusion rate (pn) of 1 − 2% roughly corresponds to
analyzing only non-synonymous variants whereas extending the analysis to include
variants in the UTR and outside the transcribed region has an inclusion rate of
approximately 10%.
We computed power for the rare variant methods on a misspecification grid with
values of pn between 0 and 0.1 and pc between 0.2 and 1.0. First we computed Type
I Error for each test by setting k = 0. The CMAT, collapsing method and WSS each
maintained the desired false positive rate for all values of pn. Type I error for the
private allele test was initially conservative for smaller values of pn, then increased
with the number of variants included, becoming anti-conservative for larger values of
pn (Supplementary Figure 3.6). Increased false positives for the private allele test were
likely due to including neutral variants in high pairwise r2, violating the independence
assumption required for the asymptotic distribution.
In the presence of causative variants (k > 0), the power to identify a gene depended
on the inclusion parameters pc and pn (Figure 2). We discuss results generated with a
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Figure 3.2: Power to analyze deep sequencing datasets for a range of inclusion prob-
abilities. Each dataset contains exact genotypes for N = 1000 cases and
controls based on k = 15 causative variants in the population. Along the
vertical axis we vary the probability of (incorrectly) including a neutral
variant (pn) in the analysis and along the horizontal axis we vary the
probability of (correctly) including a causative variant (pc). The height
of the bars in each cell indicates the power for the four tests at α = 0.01.
56
sample size of N = 1000 and k = 15 causative variants; results for k = 7 and k = 30
were similar (not shown). When all variants were correctly specified (pc = 1, pn = 0),
the CMAT, WSS and collapsing test attained power near 100% and the private test
a power of 72%, indicating that each test is quite powerful under perfect filtering.
However, power for each test dropped when we allowed for misspecification. Increas-
ing the probability of including neutral variants (pn ↑) reduced power. Decreasing
the probability of including causative variants (pc ↓) also lowered power.
A comparison of power between tests illustrates that the CMAT and WSS had
nearly identical performance and were the most powerful tests at all levels of mis-
specification considered. The private allele test had power < 20% for most parameter
settings. Power for the CMAT, WSS and collapsing test was nearly identical when
only a small number of neutral variants were included in the test statistic (pn ≤ 0.02).
Here, the absolute power for the three tests was heavily dependent on the inclusion
rate for causal variants, increasing from 30% up to 95% as the number of causal
variants included increased.
The CMAT and WSS showed a clear power gain over the collapsing method for
larger neutral variant inclusion probabilities. In fact, the power gain was greatest
when filtering accuracy was poorest. The CMAT had power of 24% compared to 11%
for the collapsing test when pn = 0.1, pc = 0.2. This trend continued for values of
pn > 0.1 (data not shown). This difference is caused by the way the different tests
account for individuals with more than one rare variant of interest. For larger values
of pn, individual samples are increasingly likely to contain multiple rare variants. By
directly testing the number of rare variants rather than the number of rare variant
carriers, the CMAT and WSS have additional power over the collapsing test.
Appropriately weighting variants in the test statistic may further improve power.
However, it is presently unclear which is the most powerful weighting strategy and it
is likely it will differ from case to case. Although we do not directly address the issue
of most powerful weighting scheme in this paper, we computed power for both the
CMAT and WSS using the weighting scheme described by Madsen and Browning[41].
Under this scheme, allele counts for the jth variant are weighted by the inverse of
the estimated standard deviation of minor allele frequency in controls. To facilitate
comparison, we included only variants with maf below our pre-determined threshold
(β = 0.05) in the analysis. The maf-based weights correspond more closely to our
disease model (Figure 1) than do the simple uniform weights and therefore provided
a more powerful analysis for both methods except when misspecification rates are
highest (Supplementary Figure 3.7). Conditional on weighting scheme, the CMAT
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and WSS had similar power across the grid.
To assess the influence of variants with maf of 1 − 5% on the presented results,
we repeated all simulations restricting attention to variants with maf ≤ 1% (ie β =
1%, pmax = 1%). The misspecification grid for these settings (Supplementary Figure
3.8) showed that overall power for each test was slightly lower than the presented
results. The noticeable change was that for the largest values of pn and pc, the WSS
showed a power advantage over the other tests with the CMAT and the collapsing
test having similar power.
For the remainder, simulation results are based on inclusion parameters of pn =
0.1, pc = 0.8 to reflect a whole-gene analysis strategy that includes non-synonymous
coding and splice-site mutations plus variants in the UTR and potential regulatory
regions flanking the gene.
3.3.2 Covariate correction
Next, we created datasets in which samples were drawn from two distinct pop-
ulations meant to resemble European and African haplotypes. We simulated the
datasets under the null hypothesis of no association (k = 0) but preferentially drew
cases from the African population. Since the African haplotypes contain more rare
variation than do the European haplotypes, the datasets contain a spurious associa-
tion between disease status and excess of rare variants. Datasets contained N = 1000
cases and controls drawn from the African population with probability p + δ, δ > 0
and p, respectively. We analyzed each dataset at α = 0.01 with the CMAT and the
covCMAT, controlling for population of origin in the latter.
We present results for p = 0.5 and 0 ≤ δ ≤ 0.25 (Figure 3). Ignoring the popula-
tion stratification resulted in an elevated CMAT Type I Error, increasing sharply for
δ > 0.025. The magnitude of this increase is affected by the inclusion probability for
the summary statistics. For strategies that attempt to capture all variants near a gene
(shown here) the false positive rate is substantially larger than for strategies focusing
on exonic variation. Controlling for ancestry by including it as a covariate into the
covCMAT maintained the desired Type I error across all values of δ considered.
3.3.3 Imputation datasets
The CMAT is easily applied to imputation datasets containing probabilistic geno-
type calls. To consider the potential of a study design combining sequenced and
imputed samples, we simulated exact genotype calls for the sequenced samples and
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Figure 3.3: Application of the covCMAT to control for population stratification.
Cases were preferentially sampled from a population containing a larger
number of rare variants. Failure to account for population stratification
leads to inflated false positive rates for the CMAT. When applied with
the covariate correction, the covCMAT maintained the appropriate Type
I Error.
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probabilistic genotypes for the remaining samples. We considered a design with an
equal number of cases and controls sequenced in a 100kb region of interest and geno-
typed for tagSNPs in a 1Mb encompassing region. Imputed samples are assumed
genotyped for the same set of tagSNPs. In this design, variants observed at least
twice in the sequenced samples are imputed in the non-sequenced samples.
Figure 3.4: Comparison of CMAT power for deep sequencing and imputation study
designs. From left to right, the bars show power at α = 0.01 for a deep
sequencing dataset with N = 200, an imputation dataset with Nseq =
200, N = 2000 and a deep sequencing dataset with N = 2000. For each,
we used the whole-gene inclusion threshold (pn = 0.1, pc = .8).
We found that the addition of imputed samples to a fixed number of sequenced
samples can provide a considerable power gain over analyzing only the sequenced
samples (Figure 4). A whole-gene CMAT analysis of datasets drawn from a population
containing k = 15 causative variants and constrained to N = Nseq = 200 sequenced
cases and controls has power of 14%. By augmenting these sequenced samples with
an additional 1800 imputed cases and controls (total sample size N = 2000), power
improves to 48%. This compares favorably with the optimal N = 2000 design that
sequences all samples and has power of 66%. Thus, the additional information from
imputed samples recovered much but not all of the power of a fully sequenced dataset.
We extended our analysis to a wide range of sample sizes with N from 200 to
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Figure 3.5: CMAT power for imputation datasets. Datasets contain exact genotypes
for Nseq sequenced cases and controls and probabilistic genotypes based
on imputation for the remaining samples. The top line shows CMAT
power when all samples are sequenced (Nseq = N) and serves as an upper
bound for power at a fixed total sample size N . We report power at
α = 0.01 using the whole-gene inclusion threshold (pn = 0.1, pc = 0.8).
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5000 and considered the effect of sequencing Nseq = 100, 200 or 400 samples for each
N . The CMAT had a well controlled type I error when applied to datasets simulated
with k = 0 causative variants (data not shown). We present results based on k = 15
causative variants in the population analyzed using whole-gene inclusion parameters
(Figure 5). Power curves for inclusion thresholds that reflect an exon-only analysis
(pn = 0.02, pc = 0.4) were slightly lower across all values of N considered (data not
shown). For comparison, we also computed CMAT power for a dataset containing
exact genotypes for all samples (i.e. Nseq = N). We found that for a given total
sample size N , CMAT power increased with the number of sequenced samples. At
N = 3000, datasets containing 100, 200 and 400 sequenced samples had powers of
48%, 56%, and 65%, respectively. To attain similar power in a set of fully sequenced
samples requires N = Nseq = 1000, 1500 and 2000 samples, respectively.
The dependence of power on the number of sequenced individuals is likely driven
by three factors. First, replacing an exact genotype with a probabilistic genotype
results in a loss of information. Thus, for a fixed sample size, datasets containing
fewer sequenced samples suffer a larger information lose. Second, increasing the
number of sequenced samples increases the chance that a risk allele is observed at
least twice and can therefore be imputed. Of k = 15 risk alleles in the maf < 5%
simulations, an average of 3.2 were observed at least twice among 100 sequenced
cases and controls. This number increased to 5.0 and 7.5 for datasets with 200
and 400 sequenced cases and controls, respectively. Third, imputation accuracy for
an individual allele improves as that allele is observed more often in the sequenced
samples. Sequencing a larger number of samples increases the number of times a risk
allele is observed, thus improving imputation accuracy for that allele.
We repeated the imputation simulations using 1% maf parameter settings (Sup-
plementary Figure 3.9). We observed only a small reduction in power compared to
the maf≤ 5% analysis. Only datasets with 100 sequenced cases and 100 sequenced
controls showed a notable reduction in power. For Nseq = 100, 200 and 400 se-
quenced cases and controls, a study with total sample size of N = 3000 had powers of
38%, 52%, and 63%, respectively. Hence, provided a sufficiently large set of sequenced
templates, imputation of rare variants is a useful strategy, even if variants with maf
< 1% are of particular interest.
3.3.4 Application to GAIN psoriasis data
Our simulation study assumed that imputation templates were sequenced indi-
viduals from the study sample. It is feasible to instead use haplotypes from a public
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dataset as the imputation templates. This has the advantage that it allows rare vari-
ant analysis in any existing GWAS dataset without requiring additional sequencing
by the investigator.
As proof of principle for this approach, we applied the CMAT to the GAIN Psori-
asis dataset consisting of 1,359 psoriasis cases and 1,400 unaffected controls of white
European ancestry. We imputed 8.2 million autosomal SNPs into the dataset us-
ing 112 CEU haplotypes from the August 2009 release of 1000 Genomes Project as
our reference panel. Previously, this dataset had been imputed for 2.5 million SNPs
using the CEU HapMap samples and analyzed with a standard single marker test
for association[49]. The strongest signal for association (rs12191877, single marker
p = 4 × 10−53) was located 13kb upstream of the HLA-C gene, a previously known
psoriasis locus on chromosome 6. Ten of the top 18 loci identified in the initial analysis
were subsequently replicated in a larger, independent sample.
To apply the CMAT, we assigned the imputed SNPs to genes and retrieved func-
tional annotations for genic variants (see Methods). We retained only SNPs with
maf< 0.05 and annotated as either non-synonymous, splice-site or UTR. In total,
2889 genes containing two or more SNPs following filtering were analyzed with the
CMAT. Of the genes tested, 55% contained two SNPs, 23% three SNPs, 11% four
SNPs and the remaining 11% contained 5 or more SNPs. None of the ten replicated
SNPs from the original analysis remained following filtering and only three genes
near a replicated signal (IL12B, TSC1 and TNFAIP3 ) were included in the CMAT
analysis.
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After Bonferroni correction for the number of genes tested, one gene achieved sta-
tistical significance: SKIV2L, (p < 10−6; p < 3 × 10−3 after Bonferroni correction)
[MIM 600478]. SKIV2L is located on 6p21.33, 700kb away from HLA-C, the previ-
ously implicated psoriasis susceptibility locus. The SKIV2L testing unit contained
four imputed variants with maf< 0.05 (Table 1). Although each variant trended
toward significance in the single marker test, no individual p-value is sufficient to
explain the level of significance observed in the CMAT. Genotypes for these variants
were uncorrelated, indicating they are likely on different haplotype backgrounds and
therefore independently contribute to the CMAT statistic. Thus, the significance of
the SKIV2L CMAT statistic is driven by the cumulative effect of the four variants.
Since imputation accuracy, indicated by Rˆ2, is high for each variant, it is unlikely
that the observed signal is the result of low imputation quality.
Analysis of common variation in the HLA region indicated the potential for
additional functional variants in the same or different genes after conditioning on
rs12191877. Our result for SKIV2L may indicate such an additional psoriasis locus
in this region and is an interesting candidate for further investigation.
3.4 Discussion
We described the CMAT, a simple method for jointly testing multiple rare vari-
ants in case-control sequence data that can be easily extended to deal with typical
challenges of modern genomic studies. Notably, our statistic accepts expected minor
allele counts from probabilistic genotypes, making it applicable to both low-coverage
sequencing and imputed data. The statistic can incorporate qualitative covariates
allowing correction for confounders such population stratification. Moreover, the
CMAT is both computationally fast and straightforward to implement.
We assessed the CMAT by applying it to simulated case-control sequencing datasets
specifically designed to contain realistic levels of neutral variation. We also considered
three alternative testing strategies, a private allele test similar to the one used by Co-
hen et al[11], the collapsing test described by Li and Leal[34] and the Weighted Sum
Statistic (WSS) of Madsen and Browning[41]. We considered levels of variant mis-
specification that are representative of exon-only sequencing to entire genic regions.
Our results indicated that the strategy of focusing on exonic variants is appropriate if
most risk rare variants are located in exons. However, if we assume that the majority
of rare risk variants are located in regulatory regions, including variants from outside
the exons may be the more powerful strategy than analyzing only exonic variants.
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That is, the increase in signal from including non-coding risk variants can outweigh
the additional noise of non-coding neutral variants. Comparing the different tests,
we noticed that the CMAT, WSS and collapsing test were equally powerful for the
exon only model. However, the CMAT and the WSS were more robust to variant
misspecification, and were therefore significantly more powerful when analyzing data
representative of whole gene analysis. The CMAT provides similar power to the WSS
and is computationally more efficient. As the WSS is based on ranking individu-
als, its computation time is bounded by the theoretical maximum of O(nlog(n)); the
computation time of the CMAT is linear with sample size. This difference can be
substantial when analyzing large sample sizes in genome-wide studies.
A pooling statistic that accepts probabilistic genotypes dramatically increases
the range of possible rare variant study designs. Our simulations demonstrated the
potential of including genotypes from both direct sequencing and imputation in the
test statistic. As genotypes for rare variants are generally imputed with higher error
rates than common variants it is important to propagate this uncertainty into the
analysis using expected minor allele counts in the CMAT, as opposed to most likely
genotype (unpublished data). Our simulation results show that substantial power can
be gained by augmenting sequencing datasets with imputed samples. In particular,
sequencing only a fraction of available individuals and imputing the remainder can
recoup much of the power of a study that sequences all samples and provides a major
cost reduction. Other methods for testing rare variants can likely be adapted to obtain
a comparable gain of efficiency from imputed data. Note that we modeled sequencing
an equal number of cases and controls, but more powerful sequencing strategies for
observing risk alleles may exist, for example sequencing mainly cases[35].
We also provided an example of a rare variant analysis that does not require se-
quencing. Instead, rare variants can be imputed into existing GWAS datasets from
publicly available reference panels. Presently, imputed rare variants are typically dis-
carded because single marker tests have limited power to detect variants with low
maf and the increased uncertainty in imputing rare variants[28]. Pooling these vari-
ants and testing their cumulative effect is more powerful and may uncover additional
signals in the data. We used the haplotypes from the CEU samples in the 1000
Genomes Project to impute rare variants into the existing GAIN Psoriasis GWAS
dataset. Our analysis shows that the CMAT can identify interesting genes that can-
not be found by single marker tests. The identified gene (SKIV2L) contains multiple
rare variants, none of which achieved genome-wide significance in a single marker
test. SKIV2L resides in the HLA region of chromosome 6 which is thought to harbor
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multiple psoriasis susceptibility genes. However, the biological interpretation is not
clear. SKIV2L is not an obvious candidate for psoriasis. While SKIV2L may be a
psoriasis locus, it is also conceivable that multiple rare variants in SKIV2L tag the
same functional common variant in another gene and the observed signal might be the
result of reverse synthetic association [16]. Further analysis is necessary to validate
this finding. The analysis was limited by the size our reference panel containing only
112 haplotypes. Only 2889 genes contained 2 or more coding variants with maf< 0.05
in this panel and were thus eligible for the pooled analysis. Future releases from the
1000 Genomes Project should provide low coverage sequencing of 2500 individuals
and deep exome resequencing of the same 2500 individuals[18]. This will increase the
number of imputable rare variants, making this analysis method more powerful.
Accurate prediction of functionally relevant sites and appropriate weighting will re-
duce variant misspecification and may further improve power of pooling methods. The
weighting scheme proposed by Madsen and Browning[41] is based on allele frequency
and is most powerful for risk variants under relatively high purifying selection[56].
Alternatively, variants can be weighted according to predictions of molecular func-
tion. In practice, bioinformatic tools such as PolyPhen[62] and SIFT[52] are useful in
predicting deleterious potential but are typically limited to coding variants. Deter-
mining functionality of non-coding variants is more difficult and although databases
containing known phenotype altering non-coding variants exist (PupaSuite[64], for
example), these are not applicable to novel variants. Instead, identifying conserved
regulatory regions within non-coding portions of a gene will be crucial in determining
which non-coding variants have phenotype altering potential and should be included
in an analysis[40]. For this paper, rather than attempting to optimize weights for our
specific disease model, we assumed very simple uniform weights and focused on the
overall performance of our test with respect to variant misspecification and imputa-
tion. However we have included a general weighing term into the statistic allowing
any desired scheme to be incorporated.
Our simulation results are based on several underlying assumptions. Like other
methods, we assume that all rare variants pooled together have the same type of
effect. That is, either all are causative, the likely model if risk variants are under
purifying selection[58], or they are all protective. If this assumption is violated and
causal and protective alleles are combined into a single statistic, pooling methods will
lose power. Our results also depend on our disease model, specifically the range of
allele frequencies and effect sizes for risk variants. The true frequency spectrum for
risk alleles will depend on the strength of purifying selection at the locus and can
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range from extremely rare family-specific mutations to so-called ‘goldilocks’ alleles
that segregate at low frequency in the population[56]. We evaluated a combination
of both models allowing frequencies between .01% and 5% for risk variants. However,
we showed that our results also apply to analyses restricted to rarer variants between
0.1% and 1%. Since we are interested in variants that would not be detected by
existing association methods, we assigned larger relative risks to rarer alleles. Our
results therefore apply to this class of risk variants and do not generalize to extremely
rare variants with Mendelian inheritance patterns. In particular, we note that our
choice of disease model explains the poor performance of the private allele test which is
best suited for testing highly penetrant Mendelian-like risk alleles segregating within
families. We have included it in our analysis because it is currently one of the few
statistical tests that has successfully provided evidence for rare variant associations.
In summary, the CMAT is a powerful and versatile tool for analyzing the con-
tribution of rare variants to the heritability of common complex diseases. The test
accounts for uncertainty in genotypes from imputation methods and can be used to
reanalyze existing GWAS datasets.
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3.5 Appendix
3.5.1 Empirical distributions for expected minor allele counts
We assume a set of cases and controls genotyped for a set of tagSNPs across a
1Mb segment that contains a 100kb region of interest. We assume Nseq cases and
controls are randomly selected and sequenced at deep-coverage in the 100kb region.
Variants observed among the sequenced samples in the region of interest are imputed
into the remaining samples.
We created empirical distributions of expected minor allele counts for imputed
genotypes assuming sequence data for Nseq = 100, 200 and 400 cases and controls and
tagSNPs for the remainder of the sample. For each, we first simulated ten independent
populations of ten-thousand 1Mb haplotypes using cosi and selected a set of tagSNPs
for each region that mimicked real-world tagging properties[67]. For each 1Mb region,
the 100 selected tagSNPs resulted in∼78% of the common variants having an r2 ≥ 0.8
with one of the selected tagSNPs, similar to the tagging properties of the Illumina
HumanHap300 BeadChip SNP genotyping platform. From each population, we drew
a random subset of 4, 000 haplotypes and treated the first 2 × Nseq as sequenced in
the middle 100kb region of interest (these sample sizes correspond to datasets with
N = 1000 and Nseq sequenced cases and controls).
We statistically phased the 2 × Nseq haplotypes across the entire 1Mb region.
These phased haplotypes then served as a reference panel for imputing the variants
observed in the middle 100kb into the remaining haplotypes. Phasing and imputation
were performed using the software program MaCH[37]. MaCH includes a ‘states’
option that speeds computation by limiting the number of haplotypes considered at
each iteration of phasing or imputation. Since our analysis focused on rare variants
that may only appear on a few haplotypes, we did not use the states shortcut. This
likely prolonged computation time but improved imputation accuracy.
We observed that imputation accuracy for rare variants was dependent on the
total number of haplotypes in the reference panel (2×Nseq) as well as the number of
times a variant was observed in the reference panel. Therefore, we created empirical
sampling distributions by binning the observed expected minor allele counts (dosage)
by true underlying genotype and the number of times the minor allele was observed
in the reference panel. We pooled analogous distributions across all ten realizations
to average over varying degrees of linkage disequilibrium. The distributions for true
heterozygotes were bimodal with peaks at 1.0, the true dosage for a heterozygote, and
0.0, the true dosage for a major allele homozygote. As the minor allele is observed
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more often in the reference panel, imputation was more accurate, indicated by the
density of the peak at 0.0 shifting to larger dosage values. Table 2 summarizes these
empirical distributions for Nseq = 100. The < 0.1 and ≥ 0.9 columns capture the
density in the two peaks. The distributions for true major allele homozygotes consist
of a point mass at 0.0 with a small amount of density just above 0.0. As the number
of minor alleles observed in the reference panel increases, the density shifts slightly
away from the point mass.
Minor Allele Count in Fraction of Heterozygote Minor Allele Dosages
Reference Haplotypes < 0.1 [0.1, 0.5) [0.5, 0.9) ≥ 0.9
1 0.729 0.120 0.063 0.088
2 0.331 0.188 0.133 0.349
3 0.291 0.169 0.128 0.413
4 0.199 0.170 0.162 0.469
5 0.327 0.176 0.162 0.335
6 0.255 0.180 0.136 0.428
7 0.166 0.149 0.132 0.553
8 0.203 0.195 0.179 0.422
9 0.091 0.114 0.128 0.667
10 0.100 0.159 0.195 0.546
11-20 0.061 0.094 0.118 0.727
21-30 0.043 0.054 0.092 0.811
31-40 0.016 0.039 0.081 0.865
41-50 0.016 0.051 0.100 0.834
51-60 0.006 0.023 0.050 0.921
61-70 0.011 0.039 0.087 0.863
71-80 0.009 0.026 0.072 0.893
81-90 0.007 0.017 0.054 0.923
91-100 0.005 0.019 0.065 0.911
Table 3.2: Summary of empirical distributions of minor allele dosage for true het-
erozygotes. Each distribution is conditional on the indicated minor allele
count in the reference haplotypes. Here we report results for Nseq = 100
sequenced cases and controls.
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Figure 3.6: Type I error rates for the rare variant tests. Power is computed at α =
0.01 on datasets with N = 1000 cases and controls at the indicated neutral
inclusion rates (pn). Type I error for the CMAT and collapsing test
(COLL) is well-controlled across values of pn. Type I error for the private
allele test (PRIV) is initially conservative then increases with pn becoming
anti-conservative.
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Figure 3.7: Power for CMAT and WSS using both uniform and maf-based weights
described in Madsen and Browning. Conditional on weighting scheme,
the CMAT and WSS have similar power across the grid. The maf-based
weights correspond more closely to our disease model than do the simple
uniform weights and therefore provided a more powerful analysis for both
methods except when misspecification rates are highest.
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Figure 3.8: Power to analyze deep sequence datasets for minor allele cutoff β = 1%.
Each dataset contains exact genotypes for N = 1000 cases and controls
based on k = 15 causative variants in the population. Along the vertical
axis we vary the probability of (incorrectly) including a neutral variant
(pn) in the analysis and along the horizontal axis we vary the probability
of (correctly) including a causative variant (pc). The height of the bars
in each cell indicates the power for the four tests at α = 0.01. Here, the
maximum allele frequency for risk variants (pmax) was set to 1%.
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Figure 3.9: CMAT power for imputation datasets with minor allele cutoff β = 1%.
Datasets contain exact genotypes for Nseq cases and controls and prob-
abilistic genotypes based on imputation for the remaining samples. The
top line shows CMAT power for Deep Sequencing datasets (Nseq = N)
and serves as an upper bound for power at a fixed total sample size N .
Here, the maximum allele frequency for risk variants (pmax) was set to
1%. We report power at α = 0.01 using the whole-gene inclusion thresh-
old (pn = 0.1, pc = 0.8).
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CHAPTER IV
A Coalescent Model for Genotype Imputation
4.1 Introduction
Genotype imputation, the estimation of genotypes at untyped markers using ref-
erence patterns of haplotype structure, has proven to be a powerful tool in mod-
ern genetic studies [38, 43]. Imputation is routinely used to increase the fraction
of the genome covered in genome-wide association studies (GWAS) thereby increas-
ing the power to detect risk variants through linkage disequilibrium (LD) mapping
[5, 9, 24, 39, 44, 74]. Large-scale meta-analyses have been made possible by imputing
a mutual set of markers into datasets genotyped on different platforms [4, 14, 82].
Imputation promises to be as important in future genetic studies that use sequencing
technology to target rare variation. Algorithms that call genotypes from sequencing
reads can be improved by including imputation methods that employ LD information,
particularly for low pass sequencing [36, 39]. Power for rare variant burden tests of as-
sociation can be increased by augmenting sequencing datasets with imputed samples;
thus providing a balance between sequencing cost and statistical power [81].
Imputation procedures involve a set of target samples in which genotypes are to be
imputed, a reference panel of phased haplotypes from which genotypes are copied and
an algorithm for applying the copying procedure. Each target samples is genotyped for
a set of single nucleotide polymorphisms (SNPs) whose genotypes serve as a scaffold
for the haplotypes of the sample; the SNPs typed in the target samples are often
selected based on patterns of LD to optimize power for LD mapping and imputation
accuracy [61]. Haplotypes in the reference panel are either more densely typed than
those in the targets, or fully sequenced. Algorithms for imputing the genotypes of
markers untyped in the target samples [7, 39, 44, 60, 68] typically employ a Hidden
Markov Model that uses the genotypes from the SNP-scaffold of each target sample
to choose the haplotypes from the reference panel that are most similar. Genotypes
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are then imputed into the target by coping the reference haplotypes that provide the
best match.
Imputation accuracy is known to depend on several factors, including reference
panel size, genetic diversity of the target population, and genetic similarity of the
reference panel and the imputation targets [2, 6, 27, 29]. For example, imputation is
likely to be most accurate when the reference panel is drawn from the same population
as the target samples, or from one that is closely related [2, 26, 39]. Densely-typed
haplotypes from the publicly available HapMap dataset [2] serve as the imputation
reference panel in most current GWAS. Although these haplotypes are usually not
derived from the same population as the GWAS target samples, they provide excel-
lent imputation accuracy for common variants in many populations [2]. Reference
panels based on sequenced haplotypes, from the 1000 Genomes Project for example
[18], will allow imputation of rarer variants. These rarer variants, however, are the
often the result of more recent mutation events than common variants. As a re-
sult, recent population history between reference haplotypes and target samples may
be more important for imputing rare variants. Next generation sequencing provides
the possibility of creating custom-made reference panels by sequencing a subset of
a large dataset to use as references for imputing variation into the remainder of the
sample. Here we determine the improvement in imputation accuracy attained with
custom-made reference panels compared to large, publicly available panels.
A thorough analysis on the effect of population subdivision on imputation accu-
racy requires a wide range of study variables, such as reference panel size and relation
to the targets, to be considered. Currently, imputation accuracy is assessed by mask-
ing a subset of known genotypes in a dataset and imputing genotypes at these sites
using an available imputation software program. Accuracy is inferred by comparing
the imputed genotypes with the true genotypes. Both real SNP data and simulated
data have served as the true underlying genotypes in this analysis design. Real data
has the advantage that it reflects true LD patterns and population structures in hu-
mans. However, the scope of investigation is limited by the amount of real data that
is available. Simulated datasets allow a wider range of scenarios to be considered.
Regardless of the underlying data type, the masking method requires performing a
large number of imputation experiments, each at a discrete set of parameter combi-
nations; a time-consuming procedure that restricts prediction of imputation behavior
across a range of study variables. Developing a method to obtain fast and accurate
estimates of imputation accuracy would allow a more detailed analysis of reference
panel characteristics that impact imputation accuracy.
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In this paper, we propose a theoretical model of imputation based on coalescent
theory [30]. Our imputation model considers a simple rule that mirrors imputation
algorithms, investigating imputation accuracy as a function of reference panel size and
population demography from which target and reference haplotypes are derived. Our
imputation rule relies on the premise that, for a given target haplotype, an imputation
algorithm will ideally choose as the template the reference haplotype with the fewest
sequence differences from the target. In our model, we take the reference haplotype
that is most closely related to the target, in terms of coalescence time, to serve as
the template since it will have, on average, the fewest sequence differences from the
target. Using this rule, we derive and analyze several equations based on coalescent
theory to quantify imputation accuracy.
A feature of the coalescent framework is its ability to model complex population
demographics, allowing a range of imputation study designs to be evaluated. Here, we
use our model to investigate the effect of population subdivision between reference and
target haplotypes on imputation accuracy. Given a set of target samples, we consider
two potential reference panels. The first is an “internal”’ reference panel of sequenced
haplotypes drawn from the same population as the target samples, and the second is
an “external”’ reference panel of sequenced haplotypes from a distinct population. In
practice, the external reference panel could be from a publicly available sequencing
dataset such as the HapMap or 1000 Genomes Projects and the internal reference
panel could be a custom-made set of sequenced haplotypes from the same dataset as
the targets. Our model predicts that internal reference panels, even when they are
considerably smaller than a competing external reference panel, are nearly always the
optimal choice for imputation. The relative improvement in imputation accuracy for
using an internal panel varies according to both the divergence time and growth rates
for the populations. As divergence time increases, small internal reference panels
can produce fewer imputation errors than much larger external panels. However,
exponential growth attenuates the effect of the divergence time, improving the relative
performance for external reference panels.
4.2 Coalescent model for genotype imputation
The coalescent is a stochastic model that describes the genealogical history of a
set of haplotype lineages [30]. A genealogy is defined by a series of coalescence events
in which pairs of lineages coalesce to form single lineages. The basic coalescent model
assumes a single homogeneous population with constant size. Given n lineages in
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a population with constant effective size of N diploid individuals, the waiting time
until the next coalescence event is exponentially distributed with rate n(n− 1)/2, in
units of 2N generations. Independent of the time of the coalescent event, one of the(
n
2
)
possible pairs of lineages is chosen to coalesce. The process proceeds iteratively
until only one lineage remains. This basic coalescent model can be extended to
accommodate more complicated modeling assumptions, such as population structure
and non-constant population size.
The coalescent algorithm described above produces a tree structure that defines
the genealogical history for a set of haplotypes sampled in the present. The lengths
of the branches of the tree indicate the times between coalescent events. Conditional
on this tree, segregating mutations can be incorporated into the model by placing
mutation events on the tree branches. This placement is typically done according to
a Poisson process, so that the rate at which mutation events accumulate is directly
proportional to coalescent time. Thus, as the coalescence time between two haplo-
types increases, the expected number of segregating sites between the two sequences
will also increase.
In this paper, we use a coalescent framework to model genotype imputation at a
non-recombining genetic locus intended to represent a short region along a chromo-
some. We assume that genotypes for a single haplotype T are to be imputed. We
define a reference panel to be a set of sequenced or densely genotyped haplotypes,
not including T but presumed to be representative of T . We assume that one haplo-
type from the reference panel will be chosen as an imputation template and that all
alleles from the template haplotype will be copied onto T . Assuming that mutations
accumulate in direct proportion to coalescent time, the reference haplotypes with the
fewest sequence differences from T are the descendants of the lineage with which T
first coalesces. If we consider an imputation algorithm that always selects the haplo-
type in the reference panel with the fewest sequence differences from T (or one such
haplotype in case of a tie), under the assumption that mutations accumulate in direct
proportion to time, the procedure used by the algorithm is equivalent to choosing the
reference haplotype with the closest genealogical history to T . Thus, jointly modeling
the genealogy of the target haplotype T and the reference haplotypes in a coalescent
framework can allow us to study the accuracy with which genotypes of T can be
imputed.
By including haplotypes from multiple reference panels in our model, we can
compare the performance of reference panels with different sizes or populations of
origin. Here, we consider a scenario with two possible reference panels for imputing
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Figure 4.1: Two population coalescent model for imputation reference panel selec-
tion. A Two populations, labeled 1 and 2, of size N1 and N2 diploid
individuals, respectively, diverge from an ancestral population of size NA
at time tD. A single haplotype T for which genotypes at untyped mark-
ers are to be imputed is sampled from population 1. We consider two
possible reference panels for imputing T : an “internal” reference panel
of n1 haplotypes sampled from population 1 and an “external” reference
panel of n2 haplotypes sampled from population 2. If T first coalesces
with a type-1 lineage (blue), then the internal reference panel is optimal
for imputing T (event C1). The external reference panel is optimal (event
C2) if T first coalesces with a lineage of type 2 (red). Finally, if T first
coalesces with a type 1-2 lineage (yellow), then the two reference panels
are equivalent for imputing T (event C12). B To compute the probability
of optimality for each reference panel we condition on D (the event that
T coalesces before the divergence), the quantities iD and jD (the number
of lineages originating in populations 1 and 2, respectively, that remain at
the time of divergence), and iC , jC and kC (the number of type 1, type 2
and type 1-2 lineages remaining at the instant when T first coalesces). In
the realization pictured, T does not coalesce before the divergence time
(event DC) and iD = 3, jD = 2, iC = 2 and jC = kC = 1. Since T first
coalesce with a type 1-2 lineage in the figure (event C12) the two reference
panels are equivalent for imputing T .
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T . The first is an “internal” reference panel consisting of n1 haplotypes sampled
from the same underlying population as T . The second is an “external” reference
panel consisting of n2 haplotypes sampled from a distinct population. Defining the
“optimal panel” as that which produces highest imputation accuracy for imputing T ,
we compute the probability of optimality for both the internal and external reference
panels and quantify the relative gain in imputation accuracy obtained by using the
optimal rather than the suboptimal panel.
To address these questions, we model the genealogical history of T and the refer-
ence haplotypes using a two-population coalescent model of divergence [66, 75](Figure
4.1A). Let the two populations be labeled 1 and 2, and assume that T is sampled
from population 1. We assume that the these populations diverged from an ancestral
population at time tD in the past and that no migration has occurred between the
descendant populations. Therefore, more recently than the divergence time (t < tD),
a lineage can coalesce only with other lineages from the same population. This as-
sumption provides a reasonable representation for pairs of populations that are ge-
ographically isolated. More anciently than the split (t > tD), all remaining lineages
are assumed to belong to a homogeneous ancestral population, and any two lineages
are allowed to coalesce, regardless of the populations from which they originate. We
assume constant effective population sizes of N1 diploid individuals for population 1,
N2 for population 2, and NA for the ancestral population.
At time t = 0, corresponding to the present, n1 reference haplotypes in addition
to the single target haplotype T are sampled from population 1 and n2 reference
haplotypes are sampled from population 2. The divergence time tD and the reference
panel sizes n1 and n2 are treated as model parameters. We refer to a lineage that
has descendants only in population 1 as a lineage of type 1. Similarly, we refer to a
lineage with descendants only in population 2 as a lineage of type 2. A lineage with
descendants in both populations is a lineage of type 1-2. Based on the assumption that
mutations accumulate in direct proportion to coalescent time, the best haplotypes for
imputing T among all available reference haplotypes are the descendants of the lineage
with which T first coalesces. Thus, the internal reference panel is optimal if T first
coalesces with a lineage of type 1 and the external reference panel is optimal if T first
coalesces with a lineage of type 2. If T first coalesces with a lineage of type 1-2, then
the two reference panels are equally appropriate for imputing T and we say that they
are both optimal.
The flexibility of the coalescent allows us to easily extend the model to include
changes in population size. To model such changes, we let N1(t), N2(t) and NA(t) be
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functions that define the size of populations 1, 2 and the ancestral populations, re-
spectively, at time t. Given the utility of population expansion models for explaining
properties of human genetic variation [13, 67], we consider a model of exponential
growth in populations 1 and 2 (Fig. 4.2). Assuming a constant-sized ancestral popu-
lation, we set N1(t) = N1e
−α1t and N2(t) = N2e−α2t for t ∈ [0, tD] and α1, α2 > 0. We
compare the results from this exponential growth model to those of the constant-size
model to determine the potential effects of human exponential growth on imputation
reference panel selection.
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Figure 4.2: The two-population coalescent model of divergence assuming exponential
growth in the descendant populations. The sizes of populations 1 and
2 change over time according to N1(t) = N1e
−α1t and N2(t) = N2e−α2t,
respectively, for t ∈ [0, tD]. The quantities α1, α2 > 0 represent growth
rates and N1, N2 represent the sizes of populations 1 and 2 in the present.
At time tD, populations 1 and 2 merge instantaneously into the ancestral
population which has a constant size NA.
4.3 Methods
We use our coalescent model of genotype imputation to determine reference panel
optimality and to quantify the differences in imputation accuracy between potential
reference panels. For th problem of imputing the target T , we first derive the probabil-
ity of optimality for both an internal reference panel of n1 haplotypes and an external
reference panel of n2 haplotypes, sampled from populations with a divergence time
of tD (in units of NA generations). Let C1 be the event that the imputation target T
first coalesces with a lineage of type 1, let C2 be the event that T first coalesces with
a lineage of type 2, and let C12 be the event that T first coalesces with a lineage of
type 1-2. It follows from our definition of optimality that P (C1), the probability that
target T first coalesces with a lineage of type 1, is the probability that the internal
reference panel is optimal for imputing T . Similarly, P (C2) is the probability that the
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external reference panel is optimal for imputing T and P (C12) is the probability that
the two reference panels are both optimal, with equal expected imputation accuracy.
In the case that exactly one reference panel is optimal, it is of interest to quantify
the improvement in imputation accuracy that results from using the optimal as op-
posed to the suboptimal reference panel. Assuming that mutations follow a Poisson
process, the expected number of sites incorrectly imputed in T is proportional to the
the time of coalescence between the target and the imputation template, the reference
haplotype from which genotypes are copied. We have assumed that an imputation
program will select the reference haplotype that has minimal coalescence time with
T , thereby minimizing the expected number of incorrectly imputed sites. It follows
that expected imputation accuracy for a given reference panel can be quantified by
using the expected time that T first coalesces with a haplotype from that reference
panel. In the following sections, we derive several measurements of imputation error,
all based on expected coalescence times, to quantify the improvement in accuracy for
one rather than the other of two potential reference panels.
4.3.1 Derivation of reference panel optimality probabilities
We consider two approaches for obtaining optimality probabilities, an exact com-
putation and a recursive computation.
4.3.1.1 Exact computations
The events C1, C2 and C12 correspond to the internal reference panel being optimal
for imputing T , the external reference panel being optimal and the two reference
panels being equally appropriate, respectively. To compute the probabilities for each
of these events, we partition the coalescent model into three components: the separate
periods in populations 1 and 2 more recently than the divergence, and the period in
which only the ancestral population is present (Figure 4.1B). Because we assume that
no migration occurs between populations 1 and 2 following their divergence from the
ancestral population, the events occurring in populations 1 and 2 more recently than
the divergence are independent and can be considered separately. Conditional on the
number of lineages from populations 1 and 2 at the divergence time, the coalescent
events in the ancestral population are independent of the events that occur more
recently than the divergence time.
First, we consider the genealogy of haplotypes in population 1 from the present
back to the divergence time tD. Define D to be the event that lineage T coalesces
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more recently than time tD and Dc to be the event that T does not coalesce by tD.
Note that if T coalesces before time tD, then the lineage with which it first coalesces
can only have descendants in population 1 and must therefore be of type 1. It follows
that if the event D occurs, then C1 also occurs and P (C1,D) = P (D). If, however,
T does not coalesce before the divergence time, it enters the ancestral population,
where it can also coalesce with lineages of types 2 and 1-2. In the latter scenario we
must consider the coalescent events in population 2 and the ancestral population.
The coalescent process in the ancestral population is dependent on the numbers
of lineages from populations 1 and 2 that survive at the divergence time. Let iD, 1 ≤
iD ≤ n1, denote the number of lineages, other than T , that originate from population
1 and survive to enter the ancestral population at the divergence time tD. Similarly,
let jD, 1 ≤ jD ≤ n2, be the number of lineages originating from population 2 that
survive at the divergence time tD. Because the coalescent processes in populations 1
and 2 are independent, jD is independent of both the quantity iD and the event D.
By conditioning on the coalescent history of T and the number of lineages from
each population remaining at the divergence time tD, we can write the quantity P (C1)
as follows
P (C1) = P (C1,D) + P (C1,Dc)
= P (D) +
n1∑
iD=1
n2∑
jD=1
P (C1,Dc, iD, jD)
= P (D) +
n1∑
iD=1
n2∑
jD=1
P (C1|Dc, iD, jD)P (Dc, iD, jD)
= P (D) +
n1∑
iD=1
n2∑
jD=1
P (C1|Dc, iD, jD)P (Dc, iD)hn2,jD(tD;N2), (4.1)
where the last equality follows from independence between populations 1 and 2 and
hn,l(t;N) is the probability that n lineages sampled from a diploid population with
effective size N coalesce down to l lineages at time t. Tavare´ [76] demonstrated that
hn,l(t;N) =
n∑
m=l
(2m− 1)(−1)m−ll(m−1)n[m]
l!(m− l)!n(l) e
−(m2 ) t2N (4.2)
where n[m] = n(n− 1) · · · (n−m+ 1) and n(m) = n(n+ 1) · · · (n+m− 1).
To obtain the probability P (Dc, iD), let Aln(t;N) be the event that n lineages in
a diploid population of effective size N coalesce down to l lineages at time t and let
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In,l =
(
n
2
)(
n−1
2
) · · · (l+1
2
)
= n!(n − 1)!/[2n−ll!(l − 1)!] be the number of ways that the
n lineages can coalesce down to l lineages [66]. Then P (Dc, iD) is derived by noting
that for DC and iD to both occur, the n1 + 1 total lineages originating in population
1 must coalesce down to iD + 1 lineages by the divergence time tD. This can occur
in In1+1,iD+1 ways. In In1,iD of these, the n1 reference haplotypes coalesce down to iD
lineages without T also coalescing. Thus,
P (Dc, iD) = P (Dc,AiD+1n1+1(tD;N))
= P (Dc|AiD+1n1+1(tD;N))P (AiD+1n1+1(tD;N))
=
In1,iD
In1+1,iD+1
P (AiD+1n1+1(tD;N))
=
iD(iD + 1)
n1(n1 + 1)
hn1+1,iD+1(tD;N1). (4.3)
The probability P (Dc) is obtained by summing over all possible values of iD
P (Dc) =
n1∑
iD=1
P (Dc, iD) (4.4)
and the probability P (D) in Equation (4.1) can be computed as
P (D) = 1− P (Dc) = 1−
n1∑
iD=1
P (Dc, iD). (4.5)
The final term to derive in Equation (4.1), P (C1|Dc, iD, jD), is the probability that T
first coalesces with a lineage of type 1 assuming that, in addition to T , iD lines from
population 1 and jD lines from population 2 survive to the ancestral population.
To derive P (C1|Dc, iD, jD) in closed form, let iC , jC , and kC be the numbers of
lineages of type 1, 2, and 1-2, respectively, remaining at the instant when T first
coalesces. The probability P (C1|Dc, iD, jD) is computed by summing over all possible
values of iC , jC , and kC ,
P (C1|Dc, iD, jD) =
min{iD,jD}∑
kC=0
min{iD,iD−kC}∑
iC=δkC,0
min{jD,jD−kC}∑
jC=δkC,0
P (C1, iC , jC , kC |Dc, iD, jD),
(4.6)
where δi,j = 1 if i = j and δi,j = 0 otherwise.
To derive the probability P (C1, iC , jC , kC |Dc, iD, jD), let N(iD, jD → i, j, k) be
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the number of ways in which iD lineages of type 1 and jD lineages of type 2 can
coalesce down to i, j, and k lineages of types 1, 2, and 1-2, respectively. Then
P (C1, iC , jC , kC |Dc, iD, jD) is given by
P (C1, iC , jC , kC |Dc, iD, jD) = N(iD, jD → iC , jC , kC)iC
IiD+jD+1,iC+jC+kC
. (4.7)
The quantity N(iD, jD → i, j, k) is derived in Appendix 4.6.1.
The probability of optimality for the external reference panel, P (C2), and the
probability that the two reference panels are equally appropriate, P (C12), are com-
puted in a similar manner to (4.1). The one notable exception is that because D
implies that the event C1 has occurred, P (C2,D) = P (C12,D) = 0. Thus, the proba-
bility that the external reference panel is optimal can be written as
P (C2) =
n1∑
iD=1
n2∑
jD=1
P (C2|Dc, iD, jD)P (Dc, iD)hn2,jD(tD;N2), (4.8)
and the probability that the two reference panels are both optimal is
P (C12) =
n1∑
iD=1
n2∑
jD=1
P (C12|Dc, iD, jD)P (Dc, iD)hn2,jD(tD;N2). (4.9)
4.3.1.2 Recursive computations
The closed-form equation for P (C1|Dc, iD, jD) is computationally intensive for
large iD and jD. In this section, we derive a more efficient recursive algorithm. Assume
that at some time t > tD, in addition to lineage T , i lineages of type 1, j lineages of
type 2 and k lineages of type 1-2 exist in the ancestral population. Conditional on
this configuration, let P˜ (C1|i, k, j) denote the probability that T first coalesces with a
lineage of type 1. We construct a recursive equation for P˜ (C1|i, k, j) by conditioning
on the lineage pair involved in the next coalescent event and considering its effect on
the subsequent coalescent process (Table 4.1).
Let m = i+j+k+1 be the total number of lineages remaining, and note that each
of the
(
m
2
)
pairs of lineages is equally likely to coalesce. There are nine unique pairs of
lineage types that can coalesce in the next event. For each pair of types, we compute
the probability that the pair will coalesce and then, conditional on their coalescence,
we compute the subsequent probability that T first coalesces with a lineage of type 1.
If the next coalescent event involves T and a lineage of type 1, an event that occurs
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Lineage Pair For Next Resulting Number of Ways
Coalescent Event Lineage Event Can Occur P (C1|Event)
T ,1 - i 1
T ,2 - j 0
T ,1-2 - k 0
1,1 1
(
i
2
)
P˜ (C1|i− 1, k, j)
1,2 1-2 ij P˜ (C1|i− 1, k + 1, j − 1)
1,1-2 1-2 ik P˜ (C1|i− 1, k, j)
2,1-2 1-2 jk P˜ (C1|i, k, j − 1)
2,2 2
(
j
2
)
P˜ (C1|i, k, j − 1)
1-2,1-2 1-2
(
k
2
)
P˜ (C1|i, k − 1, j)
Table 4.1: Derivation of the recursion P˜ (C1|i, k, j). Assume that, in addition to lin-
eage T , i lineages of type 1, j lineages of type 2 and k lineages of type
1-2 exist in the ancestral population at some time t > tD. Conditional
on this configuration, let P˜ (C1|i, k, j) denote the probability that T first
coalesces with a lineage of type 1. Column 1 lists each possible lineage
pair for the next coalescent event. Column 2 gives the resulting lineage
type for the coalescent event. Column 3 contains the number of ways each
event can occur. Column 4 gives the probability that T first coalesces with
a lineage of type 1, conditional on the pair of lineages in column 1 being
the next to coalesce. The recursive equation for P˜ (C1|i, k, j) is attained by
conditioning on all the possible lineage pairs for the next coalescent event.
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with probability i/
(
m
2
)
= 2i
m(m−1) , then the event C1 occurs. Alternatively, if the next
coalescent event occurs between T and either a lineage of type 2 or 1-2, events that
occur with probabilities 2j
m(m−1) and
2k
m(m−1) , respectively, then the event C1 cannot
occur. For the remaining lineage pairs, T is not involved in the next coalescent event
and the probability of the event C1 depends on the lineage pair that is involved in
the event.
If two lineages of type 1 coalesce, an event that occurs with probability
(
i
2
)
/
(
m
2
)
=
i(i−1)
m(m−1) , then the number of type 1 lineages is reduced by one. Thus, the probability of
event C1, conditional on two lineages of type 1 coalescing is P˜ (C1|i−1, k, j). Following
this logic, if two lineages of type 2 coalesce, an event that occurs with probability
j(j−1)
m(m−1) , then the conditional probability of event C1 is P˜ (C1|i, k, j − 1). Similarly,
if two lineages of type 1-2 coalesce, an event that occurs with probability k(k−1)
m(m−1) ,
then the conditional probability of event C1 is P˜ (C1|i, k − 1, j). If a lineage of type
1 coalesces with lineage of type 2, then the number of type 1-2 lineages increases
by one while the numbers of type 1 and type 2 lineages each reduces by one. This
occurs with probability 2ij
m(m−1) and the conditional probability of event C1 is then
P˜ (C1|i− 1, k + 1, j − 1).
Finally, if the next coalescent event involves a type 1-2 lineage and either a type
1 or type 2 lineage the resulting lineage will be of type 1-2. Thus, such an event
has the effect of reducing either the number of type 1 or type 2 lineages by one. A
coalescence between a type 1-2 and a type 1 lineage occurs with probability 2ik
m(m−1)
and, conditional on this, event C1 occurs with probability P˜ (C1|i− 1, k, j). Similarly,
the probability thst the next coalescent event involves a type 2 and a type 1-2 lineage
is 2jk
m(m−1) . The probability of C1 following this event is P˜ (C1|i, k, j − 1).
By conditioning on the possible lineage pairs for the next coalescent event, we
obtain the following recursive equation,
P˜ (C1|i, k, j) = 2i
m(m− 1) +
i(i− 1) + 2ik
m(m− 1) P˜ (C1|i− 1, k, j)
+
2ij
m(m− 1) P˜ (C1|i− 1, k + 1, j − 1)
+
j(j − 1) + 2jk
m(m− 1) P˜ (C1|i, k, j − 1) +
k(k − 1)
m(m− 1) P˜ (C1|i, k − 1, j).
(4.10)
Equation (4.10) holds for i > 0, k, j ≥ 0. P˜ (C1|0, k, j) = 0 for all k, j ≥ 0 because
there must be at least one lineage of type 1 for event C1 to occur. The recursion is
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incorporated into equation (4.1) by replacing P (C1|Dc, iD, jD) with P˜ (C1|iD, 0, jD).
The terms P (C2|Dc, iD, jD) in Eq. (4.8) and Pr(C12|Dc, iD, jD) in Eq. (4.9) can
be evaluated in a recursive fashion following the logic used to obtain Eq. (4.10). Let
P˜ (C2|i, k, j) be the probability that T first coalesces with a lineage of type 2. Then
P˜ (C2|i, k, j) = 2j
m(m− 1) +
i(i− 1) + 2ik
m(m− 1) P˜ (C2|i− 1, k, j)
+
2ij
m(m− 1) P˜ (C2|i− 1, k + 1, j − 1)
+
j(j − 1) + 2jk
m(m− 1) P˜ (C2|i, k, j − 1) +
k(k − 1)
m(m− 1) P˜ (C2|i, k − 1, j).
(4.11)
Equation (4.11) holds for i, k ≥ 0, j > 0. P˜ (C1|i, k, 0) = 0 for all k, j ≥ 0 because
at least one lineage of type 2 must be present for event C2 to occur. Eq. (4.11) can
replace P (C2|Dc, iD, jD) in Eq. (4.8).
Finally, conditional on i, j, and k, let P˜ (C12|i, j, k) be the probability that T first
coalesces with a lineage of type 1-2. P˜ (C12|i, j, k) can be written in recursive form as
P˜ (C12|i, k, j) = 2k
m(m− 1) +
i(i− 1) + 2ik
m(m− 1) P˜ (C12|i− 1, k, j)
+
2ij
m(m− 1) P˜ (C12|i− 1, k + 1, j − 1)
+
j(j − 1) + 2jk
m(m− 1) P˜ (C12|i, k, j − 1) +
k(k − 1)
m(m− 1) P˜ (C12|i, k − 1, j).
(4.12)
The boundary condition for Eq. (4.12) is
P˜ (C12|i, 0, 0) = P˜ (C12|0, 0, j) = P˜ (C12|0, 0, 0) = 0,
since at least one lineage of type 1 and one lineage of type 2 must remain to allow
the potential for a type 1-2 lineage in the future. The recursion is incorporated into
Eq. (4.9) by replacing P (C12|T cD, iD, jD) with P˜ (C12|iD, 0, jD).
4.3.2 Derivation of expected coalescent times
In this section, we quantify and compare imputation accuracy for internal and
external reference panels. Let S1 be the number of sites that are incorrectly imputed
when using an internal reference panel and let S2 be the number of sites incorrectly
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imputed when using an external reference panel. In the following, we compute the ex-
pected number of incorrectly imputed sites, E[S1] and E[S2], assuming that mutation
events accumulate in direct proportion to coalescent time.
Let the random variable T1 be the waiting time until lineage T first coalesces with
a lineage that has descendants in the internal reference panel, that is, a type 1 or
type 1-2 lineage. Let T2 be the waiting time until T first coalesces with a lineage
that has descendants in the external reference panel, that is, a type 2 or type 1-2
lineage. Here, T1 and T2 are measured in units of generations. We assume that
an imputation algorithm will select as the imputation template one of the reference
haplotypes whose coalescence time with the target T is the shortest (Figure 4.3).
Thus, the total branch length separating the target from the template is 2T1 when
the internal reference panel is used, and 2T2 when the external reference panel is
used. Under our model, mutations that occur along the branches between the target
haplotype and the template haplotype will be incorrectly imputed.
n
1
n
2
T
T
2
T
1
t
D
Figure 4.3: Coalescent times between the target T and the reference panels. T1 indi-
cates the time at which the target haplotype T first coalesces with a type
1 (blue) or type 1-2 lineage (yellow). We choose one of the descendant
reference haplotypes from that coalescent event (highlighted in purple) to
be the template from the internal reference panel. We assume when using
the internal panel mutations that result in incorrectly imputed sites arise
in direct proportion to 2T1, the coalescent time separating the target T
and the templates from the internal panel. Similarly, T2 is the time at
which the target haplotype T first coalesces with a type 2 (red) or type 1-
2 lineage (yellow) and 2T2 is the coalescent time between T and potential
templates from the external reference panel (highlighted in green). We
use E[T2−T1] to measure the expected difference in number of incorrectly
imputed sites between using the external and internal reference panels.
We model mutation events using the infinite sites model [77] and assume the
89
number of mutations that occur along a branch of length t in the genealogy follows a
Poisson distribution with mean µ`t, where µ is the per-base per-generation mutation
rate and ` is the length of the target haplotype is units of bases. Therefore, the
expected number of sites incorrectly imputed when the internal reference panel is
used is given by
E[S1] = E[E[S1|T1]] = E[2µ`T1] = 2µ`E[T1]. (4.13)
Similarly, the expected number of sites incorrectly imputed based on the external
reference panel is
E[S2] = 2µ`E[T2]. (4.14)
It follows that the expected difference in number of sites incorrectly imputed
between the external and internal reference panels is
E[S2 − S1] = 2µ`E[T2 − T1] = 2µ`{E[T2]− E[T1]} (4.15)
so that, up to a constant, deriving E[T1] and E[T2] is sufficient to determine the
expected difference.
4.3.2.1 Derivation of E[T1]
To compute the expected waiting time E[T1] until T first coalesces with a lineage
with descendants in the internal reference panel, we condition on the population in
which lineage T first coalesces.
As in Section 4.3.1, let D be the event that lineage T first coalesces in population
1 and let Dc be the complement of event D. Conditioning on event D, we have
E[T1] = E[T1|D]P (D) + E[T1|Dc]P (Dc). (4.16)
Here, P (D) and P (Dc) are obtained using Equations (4.5) and (4.4). We now compute
the expectations E[T1|D] and E[T1|Dc].
To obtain the expected waiting time E[T1|D] until lineage T first coalesces, given
that it coalesces in population 1, we can integrate the conditional survival function
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ST1|D(t) of T1 given D. The conditional survival function is defined by
ST1|D(t) = P (T1 ≥ t|D)
= 1− P (T1 < t|D)
= 1− P (T1 < t,D)/P (D)
= 1− P (T1 < min{t, tD})/P (D)
= 1− 1
P (D)
n1+1∑
i=2
P (T1 < min{t, tD}|Ain1+1(min{t, tD}))P (Ain1+1(min{t, tD}))
= 1− 1
P (D)
n1+1∑
i=2
[
1− In1,i−1
In1+1,i
]
hn1+1,i(min{t, tD};N1)
= 1− 1
P (D)
n1+1∑
i=2
[
1− i(i− 1)
n1(n1 + 1)
]
hn1+1,i(min{t, tD};N1). (4.17)
In the sixth equality, the probability that lineage T does not coalesce when the sam-
pled n1 + 1 lineages coalesce to i lineages is given by In1,i−1/In1+1,i, by the same
argument used to derive Equation (4.3). Therefore, the probability that lineage T
does coalesce is given by 1− In1,i−1/In1+1,i.
To obtain the expectation E[T1|D], we integrate ST1|D(t)
E[T1|D] =
tD∫
t=0
ST1|D(t)dt
=
tD∫
t=0
[
1− 1
Pr(D)
n1+1∑
i=2
[
1− i(i− 1)
n1(n1 + 1)
]
hn1+1,i(min{t, tD};N1)
]
dt. (4.18)
The term Pr(D) in Equation (4.18) is given by Equation (4.5). Although the integral
in Equation (4.18) can be carried out analytically, we present the formula in its
current form because numerical instabilities require that the integral be performed
numerically using an asymptotic approximation to the term hn1+1,i(min{t, tD}). In
this case, we use the asymptotic approximation of Griffiths [63]. Furthermore, it
is easier to modify Equation (4.18) from the form given to account for exponential
growth.
The quantity E[T1|Dc] is the expected time until lineage T first coalesces in the
ancestral population with a lineage with descendants in population 1, given that it
does not coalesce in population 1. This expected time can be found by conditioning
91
on the number iD of lineages of type 1 that remain at the divergence time:
E[T1|Dc] =
n1∑
iD=1
E[T1|iD,Dc]Pr(iD|Dc)
=
n1∑
iD=1
4NA
iD + 1
Pr(Dc, iD)
Pr(Dc) . (4.19)
Here, we used the fact that 4N/(n+ 1) is the expected time until a lineage coalesces
with any of n other lineages in a population of diploid size N . Pr(Dc, iD) and Pr(Dc)
are found using equations (4.3) and (4.4), respectively. The quantity E[T1] is then
obtained by plugging Equations (4.18), (4.19), (4.5), and (4.4) into Equation (4.16).
4.3.2.2 The expectation E[T2]
The expected coalescence time E[T2] between T and the best template in the
external reference panel is much simpler to derive. To compute E[T2], we simply
condition on the number jD of lineages of type-2 that remain at the divergence time.
E[T2] =
n2∑
jD=1
E[T2|jD]hn2,jD(tD)
=
n2∑
jD=1
4NA
jD + 1
hn2,jD(tD;N2), (4.20)
where, as in Equation (4.19), we have used the fact that the expected waiting time
until lineage T coalesces with jD other lineages in the ancestral population is given
by 4NA/(jD + 1). This completes the derivation of the expectations E[T1] and E[T2]
in the case in which populations 1 and 2 are of constant size.
4.3.3 Derivations of probabilities and expectations under exponential
growth
Let N1(t) and N2(t) be the sizes of populations 1 and 2 at time t < tD. We model
exponential growth in populations 1 and 2 between the present and the divergence by
setting N1(t) = N1(0)e
−α1t and N2(t) = N2(0)e−α2t (Figure 4.2). Thus far, our equa-
tions have been derived assuming constant population sizes. Changes in population
size affect the time scale at which coalescent events within that population occur.
Thus, to account for changing population sizes in the exponential growth model, we
use a transformation method that scales coalescent time in a constant-sized popula-
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tion to obtain coalescent rates that apply to an exponentially growing population [53].
The equations derived in the previous sections can then be applied to the exponential
growth model simply by rescaling coalescent time.
Counting from time t = 0, let t denote coalescence time in a population of size
N(t) = N(0)e−αt, t ∈ [0,∞). Let t′ denote the transformed time in a population of
constant size one, where the size of one is chosen for simplicity. Following [53], the
transformation g(t;N(0), α) that converts time t in the growing population to time
t′ in the population of constant size one is given by
g(t;N(0), α) =
t∫
0
1/N(z)dz =
{
eαt−1
N(0)α
, if α 6= 0,
t, otherwise.
(4.21)
All of the changes under exponential growth are accomplished by modifying the
probability hn,k(t;N) that n lineages coalesce to k lineages in time t in a population
of diploid size N (Equation 4.2). Under exponential growth, the distribution of the
number of lineages remaining at time tD in a population with size at time t given by
N(t) = N(0)e−αt is the same as the distribution of the number of lineages remaining
at time t′D = g(tD;N(0), α) in a population of constant size 1. Thus, under growth
rate α, Equation (4.2) becomes
hn,k(t;N(0), α) =
n∑
i=k
(2i− 1)(−1)i−kk(i−1)n[i]
k!(i− k)!n(i) e
−(i2)g(t;N(0),α). (4.22)
By changing hn,k(t;N)→ hn,k(t;N(0), α) to accommodate growth, all of the equa-
tions in Sections 4.3.1 and 4.3.2 are easily reformulated to account for exponential
growth. The modified equations and their dependencies are summarized in the ap-
pendix (section 4.6.2).
4.4 Results
4.4.1 Consistency of computations
We derived exact closed-form (Section 4.3.1.1) and recursive equations (Section
4.3.1.2) for computing the probabilities P (C1), P (C2) and P (C12). Both the exact
and recursive computations require the function hn,k(t;N) for be evaluated. The form
given by Tavare´ (Eq. 4.2) is numerically unstable for small t and large n. Griffiths
showed that, as t → 0 and n → ∞, hn,k(t;N) converges to a normal distribution
([63], Thm. 2). Therefore, for n < 40 we use Eq. 4.2 for hn,k(t;N) and Griffiths’
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normal approximation for n ≥ 40.
Table 4.2 gives values of P (C1) computed using both the exact and recursive forms
at two divergence times (tD) and for different reference panel sizes (n1 and n2). For
larger values of n1 or n2, closed-form derivation of P (C1) becomes computationally
unattainable. The probabilities are identical for the exact and recursive methods at
parameter values where a comparison is possible. We also find that these analytic
values agree with estimates based on coalescent simulations of our model. Since the
exact, recursive and simulation computations agree, we employ the recursive form to
allow large reference panel sizes to be considered.
tD = 0.01 tD = 0.05
n1 n2 Closed-form Recursion Simulation Closed-form Recursion Simulation
1 1 0.3400 0.3400 0.3405 0.3658 0.3658 0.3659
1 5 0.1221 0.1221 0.1220 0.1648 0.1648 0.1650
1 10 0.0726 0.0726 0.0727 0.1191 0.1191 0.1190
5 5 0.4069 0.4069 0.4047 0.5083 0.5083 0.4996
5 10 0.2807 0.2807 0.2788 0.4164 0.4164 0.4094
10 10 0.4392 0.4392 0.4377 0.6051 0.6051 0.5993
50 50 − 0.6068 0.6055 − 0.8789 0.8770
50 100 − 0.5378 0.5369 − 0.8680 0.8666
100 100 − 0.7268 0.7262 − 0.9494 0.9498
Table 4.2: P (C1) computed analytically using closed form and recursive equations
and estimated using coalescent simulations.
4.4.2 Constant-sized populations
We first present results for equal, constant-sized populations (N1 = N2 = NA).
For a range of reference panel sizes n1 and n2 and at several divergence times tD (in
units of 2NA generation), we give the optimality probability for an internal reference
panel, P (C1), and the expected difference in number of incorrectly imputed sites
between the external and internal reference panels, E[S2 − S1] (Figure 4.4). Positive
values for E[S2 − S1] indicate the additional number of sites that are incorrectly
imputed, on average, by using the external reference panel instead of the internal
panel. A negative value indicates that the external reference panel will result in
fewer imputation errors and a value of zero indicates the same number of expected
imputation errors using the internal and external panels. E[S2 − S1] is reported in
units of the scaled population mutation rate for the imputed region.
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Figure 4.4: Imputation performance for the constant-size two population model.
(A,C,E) The probability P (C1) that the internal reference panel is op-
timal, computed for divergence times of tD = 0, 0.01, and 0.05. (B,D,F)
The expected difference in the number of sites incorrectly imputed
E[T2 − T1] when imputation is performed using the external reference
panel rather than the internal reference panel, for divergence times of
tD = 0, 0.01, and 0.05. E[T2 − T1] is reported in units of the population
scaled mutation for the imputed region.
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A divergence time of tD = 0 corresponds to no subdivision between the pop-
ulations and is included to allow comparison with models that contain a non-zero
divergence. In our model, the divergence time is approximately Fst, a measure of
population differentiation. We present a divergence time of tD = 0.01 to represent
differentiation observed between two European populations and tD = 0.05 to repre-
sent more distantly-related human populations [51].
For a divergence time of tD = 0, the internal and external reference panels are both
from the same population as the target and the only difference between them is size.
Not surprisingly, given two reference panels from the same population, the larger of
the two is more likely to be optimal (Fig 4.4 A). Larger reference panels are also likely
to result in fewer sites incorrectly imputed (Fig 4.4 B). Increases in reference panel
size initially result in large improvements for both P (C1) and E[S2 − S1] compared
to a competing reference panel of fixed size. However, we observe an asymptotic
behavior indicating a diminishing return for increasing reference panel size beyond a
certain point. This can be seen in Figure (4.4B) where, for a fixed reference panel
size n1, increasing the competing reference panel size n2 from 50 to 100 and then
from 100 to 500 leads noticeable improvements in accuracy. However, increasing n2
beyond 500 up to 1000 results in only a very modest improvement.
When the divergence time between populations 1 and 2 is nonzero, the internal
reference panel is nearly always optimal for a large portion of the parameter space of
n1 and n2 (Fig 4.4 B, C, E, F). For tD = 0.01, P (C1) increases sharply with n1 for all
values of n2 considered. We observe that even for n2 >> n1, the probability that the
internal reference panel is optimal can be quite large. For example, P (C1) = 0.647
for an internal reference panel of n1 = 100 haplotypes and an external reference
panel ten times larger with n2 = 1000 haplotypes. Once the internal reference panel
contains n1 = 500 haplotypes, it is nearly always optimal (P (C1) ≈ 1) regardless
of the size of the external reference panel. Increasing divergence time tD to 0.05
continues the trends observed for tD = 0.01. Here, the internal reference panel is
nearly always optimal for n1 ≥ 200. In fact, for sufficiently large n1, the probability
of optimality for the internal reference panel is nearly independent of the size of the
external reference panel.
With a nonzero divergence time, we also observe that internal reference panels that
are smaller than a competing external reference panel can result in fewer expected
imputation errors. The relative sizes of internal and external reference panels that
provide similar accuracy depends on the divergence time (Fig 4.4 D, F). For tD = 0.01,
an internal reference panel of n1 = 50 results in approximately the same number of
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incorrectly imputed sites as an external panel of size n2 = 100. As the internal
reference panel becomes larger, it takes substantially more haplotypes in the external
reference panel to achieve similar accuracy. For example, 1000 haplotypes are required
in an external panel to provide the same accuracy as an internal reference panel of only
n1 = 80 haplotypes. When the divergence time increases to tD = 0.05, we observe
that an internal reference panel as small as n1 = 20 haplotypes can provide better
imputation accuracy than much larger external reference panels. Further increases in
the size of the internal reference panel continue to improve accuracy. However after
approximately n1 = 60 haplotypes, the increase in accuracy for additional internal
reference haplotypes begins to diminish.
4.4.3 Exponentially growing populations
We next computed P (C1) and E[S2 − S1] assuming exponential growth in popu-
lations 1 and 2 beginning at the divergence and continuing to the present. Here we
assume that both populations have size NA at the divergence t = tD and size 100NA
in the present time t = 0. For the exponential growth model, we present results for
divergence times of tD = 0.01, 0.05 and 0.1 (in units of 2NA generation). We include
lines for both the exponential growth and constant-sized models in each plot (Fig 4.5)
to allow comparison of results between the two models.
At each divergence time, compared to the constant size model, exponential growth
reduces the probability P (C1) that the internal reference panel is optimal (Fig 4.5
A,C,E). The difference in expected number of incorrectly imputed sites E[S2 − S1]
also decreases under the exponential growth model (Fig 4.5 B,D,F). The reduction
is greatest for the smallest divergence time tD = 0.01, for which the large external
reference panels (n2 = 500, 1000) are either more optimal or equally appropriate
versus internal panels of n1 = 300 or less haplotypes. Also for tD = 0.01, E[S2 − S1]
is negative for these large external reference panels compared to internal reference
panels of up to n1 = 225 haplotypes. This indicates that for exponentially growing
populations separated by small divergence times, there is an advantage to using the
large external reference panels compared to smaller and even moderately sized internal
panels.
For a divergence time of tD = 0.05, exponential growth still reduces P (C1) com-
pared to the constant-size model but here a large external panel is only optimal over
smaller internal reference panels (n1 ≤ 50). Once an internal reference panel con-
tains 200 haplotypes it is still optimal more than 80% of the time compared to large
external panels (Fig 4.5 C). In terms of E[S2 − S1], under the exponential growth
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Figure 4.5: Imputation performance for the exponential growth two-population
model. (A,C,E) The probability P (C1) that the internal reference panel
is optimal, computed for divergence times of tD = 0.01, 0.05 and 0.1.
Values for the exponential growth model are plotted with dashed lines
and, for comparison, the equivalent values for a constant-size model are
shown with solid lines. (B,D,F) The expected difference E[T2−T1] in the
number of sites incorrectly imputed when imputation is performed using
the external reference panel rather than the internal reference panel, for
divergence times of tD = 0, 0.01, and 0.05. E[T2−T1] is reported in units
of the population scaled mutation rate for the imputed region.
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model at tD = 0.05, an internal panel of n1 = 70 haplotypes gives the same expected
number of incorrectly imputed sites as an external panel with n2 = 500 or 1000 hap-
lotypes (Fig 4.5 D). The results represent a dramatic change from the constant-size
model in which, for equivalently sized panels, the internal panel offers a considerable
improvement in accuracy over the large external panels.
The trend of decreasing both P (C1) and E[S2 − S1] continues for tD = 0.1 with
even larger reductions observed (Fig 4.5 E, F). However, for a divergence time this
large, the values for P (C1) and E[S2 − S1] under the constant model favor internal
panels to such an extent that relatively small internal panels (n1 = 40) provide better
imputation performance than a large external panel.
4.5 Discussion
We have introduced a theoretic model of genotype imputation accuracy, employing
the coalescent framework to model the ancestry of reference and imputation target
haplotypes, taking the reference haplotype with the most similar genealogical history
to the target to be the template for imputation and using the expected coalescence
time between the target and the template haplotype to predict the expected number
of incorrectly imputed sites in the target. Framing imputation in a coalescent model
has two major benefits. First, the coalescent allows analytic equations to be derived
for imputation accuracy, providing a computationally fast method for predictive im-
putation analysis across a continuous range of study design variables. Second, the
coalescent allows complex modeling of the population histories, so that virtually any
relationship between the reference and target populations can be considered.
Here, we used the model to determine the effects of population subdivision on
imputation accuracy. In particular, we compared the performance of internal reference
panels drawn from the same source population as the target to external reference
panels drawn from distinct, yet closely related populations. In the specific model we
considered, the populations containing the internal and external panels diverged from
an ancestral population in the past, after which, no migration has occurred between
the two populations. The model predicts that even when an internal reference panel
is considerably smaller than an external reference panel, the internal panel is nearly
always optimal in the sense that it contains the haplotype with the closest genealogical
history to the target. As divergence time between the populations containing the
reference panels increases, it becomes nearly impossible for even very large external
reference panels (1000 haplotypes) to be optimal compared to an internal reference
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panel. This result was observed both for the constant size and exponential growth
population models, with exponential growth providing a slight improvement in the
probability of optimality for external panels when compared to the constant size
model.
Although an internal reference panel is nearly always optimal, the relative im-
provement in imputation accuracy for using an internal panel varies according to
divergence time between the reference panel populations. For constant-sized popu-
lations, we observed that very large external reference panels can provide the same
accuracy as a modestly sized internal reference panel for small divergence times. As
divergence time increases, a small internal reference panel will provide more accu-
rate imputation than a large external panel. However, if the populations experience
exponential growth following the divergence, the magnitude of the expected num-
ber of additional errors is significantly reduced when compared to constant sized
populations. Thus, exponential growth attenuates the effect of the divergence time,
improving the relative performance of an external reference panel in terms of both
optimality probability and imputation accuracy.
The results from our model have implications for imputation strategies in fu-
ture population-based genetic association studies. Currently, large publicly-available
datasets such as HapMap and the 1000 Genomes Project are commonly used for im-
putation reference panels. However, next generation sequencing technology will allow
investigators to create custom-made internal reference panels from the same source
population as their study sample. Our results suggest that such a custom-made ref-
erence panel will nearly always improve imputation accuracy even if it is considerably
smaller than an existing reference panel based on the 1000 Genomes Project. The
quantitative improvement, however, may be small if the existing panel is very large
and not too distantly related to the imputation targets in the study sample. The
advantage of an internal reference panel will be in its ability to accurately impute
rare population-specific variants that exist in the study sample but do not exist in a
reference panel from an external population.
We have assumed no migration between the present-day populations in our model.
Relaxing this assumption will likely lead to changes in our results. Notably, migra-
tion allows the target haplotype to coalesce with a lineage ancestral to the external
reference panel more recently than the divergence time. This coalescence can occur if
either the target migrates to the population containing the external reference panel
or if an ancestor of an external reference haplotype migrates to the population con-
taining the target. Therefore, including migration in the model is likely to reduce
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the expected coalescence time between the target and an ancestor of the external
reference panel, improving the probability of optimality and accuracy for an exter-
nal reference panel. The extent of the improvement is unclear and requires further
investigation.
We note that our analysis for expected number of incorrectly imputed sites as-
sumes perfect information for the haplotypes in the reference panel, including both
perfect phasing and that all sites are correctly called. Perfect phasing would likely re-
quire information from parental haplotypes and is not realistic for most studies. The
assumption that all sites are correctly called is also not realistic for most sequencing
experiments, especially for low-coverage sequencing. In practice, these assumptions
may not be met, and differences in the data quality between competing reference
panels can lead to imputation results that differ from our predictions. If the source
of error can be specified by a model, it can potentially be included in our analysis.
For example, the probability that a site in a reference haplotype is correctly called in
a sequencing experiment is dependent upon sequencing depth, allele frequency of the
variant and the specific calling algorithm (personal communication, Shyam Gopalakr-
ishnan). Estimates of these probabilities based on empirical data or simulations can
be incorporated into our equations to compute the expected number of sites incor-
rectly imputed conditional on the probability distribution for sites to be called in the
reference panel.
Finally, to mimic computational imputation algorithms, we used the rule that the
reference haplotype with minimal coalescent time between itself and the target serves
as the imputation template. Thus, the only source of imputation error in our model
is in mutations that occur after the coalescence of the target and the template. In
reality this is likely a best-case scenario since additional sources of error may result
from the imputation software. For example, our model assumes that the entire length
of the target haplotype is imputed using the same reference haplotype. However, due
to recombination events in the past, a real target haplotype is likely to be composed
of multiple segments, each with a unique reference haplotype that provides the best
template for imputation. Our model, therefore, implicitly assumes that an imputation
algorithm will always correctly jump between reference haplotypes when imputing a
target. It is not clear how realistic this assumption is in practice, and provides an
additional source of imputation error that is not treated in our model.
Genotype imputation is a valuable tool in genetic studies of complex disease. Op-
timizing imputation accuracy is important for obtaining valid analysis results based
on the imputed data. In this chapter, we have introduced a coalescent model of
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genotype imputation and showed that it can be used to predict accuracy for a range
of imputation study designs. We have demonstrated that the model can be used to
compare the performance of competing reference panels, and we anticipate that it
will be useful in optimizing imputation performance in future genetic studies.
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4.6 Appendix
4.6.1 The quantity N(iD, jD → iC , jC , kC)
Here we derive the number of ways N(iD, jD → iC , jC , kC) in which iD lineages
of type 1 and jD lineages of type 2 can coalesce down to iC , jC , and kC lineages
of types 1, 2, and 1-2 at the moment when lineage T first coalesces. This quantity
is used to obtain the closed-forms of the probabilities Pr(C1), Pr(C2), and Pr(C12)
(Equations 4.1, 4.8, and 4.9).
To derive an expression for N(iD, jD → iC , jC , kC), note that if kC lineages of
type 1-2 remain at the time immediately before the first coalescence involving lineage
T , then at least kC lineages of type 1, and at least kC lineages of type 2 must combine
together to produce these lineages. Let i∗D and j
∗
D be the numbers of lineages of type
1 and type 2, respectively, that combine to create the kC lineages of type 1-2 (figure
4.6). Specifically, let i∗Dr lineages of type 1 and j
∗
Dr
lineages of type 2 combine to
make the rth lineage of type 1-2. The possible values of i∗D1 , ..., i
∗
DkC
are given by
all possible partitions of i∗D objects into kC nonempty subsets. Similarly the possible
values of the j∗D1 , ..., j
∗
DkC
are given by all possible partitions of j∗D objects into kC
nonempty subsets.
Let P (n, k) denote the number of partitions of an integer n into k positive integers.
Let piq(n, k) = (piq1(n, k), ..., pi
q
k(n, k)) denote the qth partition of this kind with pi
q
r(n, k)
denoting the rth part in the partition. We can permute the k parts of the qth
partition in k! ways. Denote the zth permutation of partition q by pi(q,z)(n, k) =
(pi
(q,z)
1 (n, k), ..., pi
(q,z)
k (n, k)). For simplicity of notation, denote the number of labeled
histories among a set of n lineages by F (n) ≡ In,1. Then the quantity N(iD, jD →
iC , kC , jC) is given by
N(iD, jD → iC , kC , jC)
=
iD−ic∑
i∗D=kc
jD−jc∑
j∗D=kc
(
iD
i∗D
)(
jD
j∗D
) P (i∗D,kC)∑
η=1
P (i∗D,kC)∑
γ=1
α(i∗D, kC , η)α(j
∗
D, kC , γ)R(i
∗
D, j
∗
D, kC , η, γ)
× IiD−i∗D,icIjD−j∗D,jc
(
iD + jD − (ic + kc + jc)
iD − i∗D, i∗D + j∗D − kc, jD − j∗D
)
. (4.23)
In Equation (4.23), the quantity α(n, k, q) is the number of ways to form the qth
partition piq(n, k) = (piq1(n, k), ..., pi
q
k(n, k)) of size k nonempty parts of n objects. To
obtain an expression for α(n, k, q), define a(ϕ; piq(n, k)) to be the number of parts of
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the partition piq(n, k) that are of size ϕ. Then α(n, k, q) is given by
α(n, k, q) =
(
n
piq1(n,k),...,pi
q
k(n,k)
)
∏k
ϕ=1 a(ϕ; pi
q(n, k))!
, (4.24)
where
(
n
piq1(n,k),...,pi
q
k(n,k)
)
is the number of ways to choose the elements in each part,
and
∏k
ϕ=1 a(ϕ; pi
q(n, k))! is the factor by which we overcount the ways to choose the
elements of the parts due to the fact that, for each way of distributing k elements
into r parts of equal size, there are r! − 1 other ways to distribute the elements in
which the same elements are grouped together.
The quantity R(i, j, k, η, γ) in Equation (4.23) is the number of labeled histories
for the i∗D + j
∗
D lineages that ultimately coalesce to form the kC lineages of type 1-2.
For given values of i∗D and j
∗
D, consider a particular partition of the i
∗
D lineages into
kC nonempty parts, and a particular partition of the j
∗
D lineages into kC nonempty
parts. Each one of the kC lineages of type 1-2 is made by combining one part from
the partition of the i∗D lineages with a part from the partition of the j
∗
D lineages.
To find all possible ways to pair up parts, we fix the indices of the parts of the j∗D
lineages and we permute the parts of the i∗D lineages with respect to them. There are
kC ! ways to pair up the parts, and these ways are indexed by z. For the zth way of
permuting the parts, the lineages in part pi
(η,z)
r (i∗D, kC) combine with the lineages in
part piγr (j
∗
D, kC) to produce the rth lineage of type 1-2.
The rth pair of parts of lineages undergoes pi
(η,z)
r (i∗D, kC)+pi
γ
r (j
∗
D, kC)−1 coalescent
events on its way down to a single lineage. Thus, there are
W (i∗D, j
∗
D, kC , pi
(η,z), piγ)
≡
(
i∗D + j
∗
D − kC
pi
(η,z)
1 (i
∗
D, kC) + pi
γ
1 (j
∗
D, kC)− 1, ..., pi(η,z)kC (i∗D, kC) + piγkC (j∗D, kC)− 1
)
(4.25)
possible ways to order the coalescent events among all pairs of partitions.
Since there are F (pi
(η,z)
r (i∗D, kC) + pi
γ
r (j
∗
D, kC)) labeled histories for the rth pair of
parts as they coalesce down to form the rth lineage of type 1-2, there are
kc∏
r=1
F (pi(η,z)r (i
∗
D, kC) + pi
γ
r (j
∗
D, kC))×(
i∗D + j
∗
D − kC
pi
(η,z)
1 (i
∗
D, kC) + pi
γ
1 (j
∗
D, kC)− 1, ..., pi(η,z)kC (i∗D, kC) + piγkC (j∗D, kC)− 1
)
labeled histories for all of the i∗D and j
∗
D lineages when paired in this way. Finally,
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we sum over all kC ! possible ways to permute the partitions of the i
?
D lineages with
respect to the partitions of the j?D lineages. This gives
R(i∗D, j
∗
D, kC , η, γ) =
kC !∑
z=1
W (i∗D, j
∗
D, kC , pi
(η,z), piγ)
kc∏
r=1
F (pi(η,z)r (i
∗
D, kC) + pi
γ
r (j
∗
D, kC)).
(4.26)
We have separately considered three parts of the labeled history of the lineages in
the ancestral population: 1) the labeled history of the iD − i∗D lineages that coalesce
to form lineages of type 1, 2) the labeled history of the i∗D + j
∗
D lineages that coalesce
to form lineages of type 1-2, and 3) the labeled history of the jD − j∗D lineages that
coalesce to form lineages of type 2. To integrate these histories into one full history
for all lineages, we must only consider how the coalescence times in each of these
histories relate to the coalescence times in the other histories. The final quantity in
Equation (4.23) is the number of ways to interweave the coalescent events in these
labeled histories.
There are iD−i∗D−iC coalescence events among the lineages that are ultimately of
type 1, there are jD−j∗D−jC coalescence events among the lineages that are ultimately
of type 2, and there are i∗D + j
∗
D − kC coalescence events among the lineages that
are ultimatelyof type 1-2. The number of ways to interweave the coalescence times
for each of these histories is equal to the number of ways to choose which of the
iD + jD − iC − jC − kC total coalescent events correspond to events within each of
these different histories. This is given by(
iD + jD − (ic + kc + jc)
iD − i∗D, i∗D + j∗D − kc, jD − j∗D
)
. (4.27)
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I
jD
iD1
iD
jD
iDk
c
jD
jD
*iD  +
*
1
2
2 kc
Figure 4.6: An illustration of N(iD, jD → iC , jC , kC).One possible way in which
iD = 15 lineages of type 1, jD = 12 lineages of type 2, and one lineage I
can coalesce down to iC = 2 lineages of type 1, kC = 3 of type 1-2, and
jC = 2 lineages of type 2, with the final coalescence occurring between I
and a lineage of type 2. Linages from G1 are in red, lineages from G2 are
in blue, and lineages with descendants in both G1 and G2 are in purple.
Here i∗D = 10 is the number of lineages of type 1 that coalesce with j
∗
D = 8
lineages of type 2 to produce the kC = 3 lineages of type 1-2. i
∗
D1
= 3 is
the number of lineages of type 1 that combine with j∗D1 = 4 lineages of
type 2 to create the first lineage of type 1-2. In general, i∗Dr is the number
of lineages of type 1 that coalesce with j∗Dr lineages of type 2 to produce
the rth lineage of type 1-2.
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4.6.2 Table of equations
Quantity Dependencies
1 g(t;N(0), α) =
{
eαt−1
N(0)α
, if α 6= 0,
t, otherwise.
2 hn,k(t;N(0), α) =
∑n
i=k
(2i−1)(−1)i−kk(i−1)n[i]
k!(i−k)!n(i)
e
−
(
i
2
)
g(t;N(0),α)
3 P(Dc, iD) = iD(iD+1)n1(n1+1) hn1+1,iD+1(tD ;N1(0), α1) 2
4 P(Dc) =∑n1iD=1 P(Dc, iD) 3
5 P(D) = 1−∑n1iD=1 P(Dc, iD) 3
6 P˜(C1|i, j, k) = 2im(m−1) +
i(i−1)+2ik
m(m−1) P˜ (C1|i− 1, k, j)
+ 2ij
m(m−1) P˜ (C1|i− 1, k + 1, j − 1)
+
j(j−1)+2jk
m(m−1) P˜ (C1|i, k, j − 1) +
k(k−1)
m(m−1) P˜ (C1|i, k − 1, j)
7 P˜ (C2|i, k, j) = 2jm(m−1) +
i(i−1)+2ik
m(m−1) P˜ (C2|i− 1, k, j)
+ 2ij
m(m−1) P˜ (C2|i− 1, k + 1, j − 1)
+
j(j−1)+2jk
m(m−1) P˜ (C2|i, k, j − 1) +
k(k−1)
m(m−1) P˜ (C2|i, k − 1, j)
8 P˜ (C12|i, k, j) = 2km(m−1) +
i(i−1)+2ik
m(m−1) P˜ (C12|i− 1, k, j)
+ 2ij
m(m−1) P˜ (C12|i− 1, k + 1, j − 1)
+
j(j−1)+2jk
m(m−1) P˜ (C12|i, k, j − 1) +
k(k−1)
m(m−1) P˜ (C12|i, k − 1, j)
9 P(C1) = P(D) +
∑n1
iD=1
∑n2
jD=1
P(C1|Dc, iD, jD)P(Dc, iD)hn2,jD (tD ;N2(0), α2) 6, 5, 3, 2
10 P(C2) =
∑n1
iD=1
∑n2
jD=1
P(C2|Dc, iD, jD)P(Dc, iD)hn2,jD (tD ;N2(0), α2) 7, 3, 2
11 P(C12) =
∑n1
iD=1
∑n2
jD=1
P(C12|Dc, iD, jD)P(Dc, iD)hn2,jD (tD ;N2(0), α2) 8, 3, 2
12 ST1|D(t) = 1−
1
Pr(D)
∑n1+1
i=2
[
1− i(i−1)
n1(n1+1)
]
hn1+1,i(min{t, tD};N1(0), α1) 5, 2
13 E[T1|D] =
∫ tD
t=0
[
1− 1
Pr(D)
∑n1+1
i=2
[
1− i(i−1)
n1(n1+1)
]
hn1+1,i(min{t, tD};N1(0), α1)
]
dt. 5, 2
14 E[T1|Dc] =
∑n1
iD=1
4NA
iD+1
Pr(Dc,iD)
Pr(Dc) 4, 3
15 E[T2] =
∑n2
jD=1
4NA
jD+1
hn2,jD (tD ;N2(0), α2) 2
Table 4.3: Summary of all derived equations and their dependencies. Formulas for
the case in which populations 1 and/or 2 are of constant size are obtained
by setting α1 and/or α2 equal to 0.
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CHAPTER V
Discussion
This dissertation has addressed several current problems in the field of human
statistical genetics. The projects were diverse, but had a unifying theme of developing
statistical methods to complement the Genome-Wide Association Study (GWAS)
and further our understanding of complex disease. In this section we discuss the
contributions of this dissertation and we address future questions and challenges.
The first project dealt with follow-up testing to characterize the true genotype-
phenotype relationship for risk variants implicated by a GWAS. We expected and
observed a bias in genetic and interaction effects estimated in a naive fashion due
to the Winner’s Curse phenomenon. Less expected and more problematic was the
observation that a follow-up hypothesis test for interaction had an elevated type I error
when the initial GWAS test did not model a potential interaction. Thus, while the
Winner’s Curse has previously been blamed for replication failure of true risk variants,
here we show that it can also cause false positives. Gene-environment interactions
are already notoriously difficult to identify and replicate and our results reinforce the
need for care in the application and interpretation of tests for interaction.
We introduced the partial likelihood Markov Chain Monte Carlo (MCMC) algo-
rithm to obtain bias-reduced estimates of gene-environment effect parameters from a
likelihood function that conditions on the initial significant GWAS test. The partial
likelihood MCMC uses a simulation-rejection step to account for the intractable por-
tion of the conditional likelihood function while the tractable portion is utilized in a
Metropolis-Hastings-like step. The algorithm has broader applications in statistical
genetics such as gene-gene interactions, and below we describe how it might be applied
to parameter estimation from burden-style tests like the Cumulative Minor Allele Test
(CMAT). The generality of the algorithm allows application to any scenario likely to
suffer from a Winner’s Curse effect, that is, parameters estimated from a dataset
that had low power to detect an association. The only requirements for the partial
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likelihood MCMC are knowledge of the initial test that was performed and the un-
conditional likelihood function from the data are derived. Beyond the ascertainment-
correction problems considered here, the partial likelihood MCMC may find further
applications where inference is required on a likelihood function that consists of both
tractable and intractable portions.
The second project was an investigation of statistical methods and study designs
to identify rare genetic variants that contribute to disease risk. By looking at the
cumulative effect of multiple rare variants, our CMAT burden statistic is more pow-
erful than individually applying GWAS-style single marker tests. More importantly,
we used the CMAT to investigate several practical challenges in the application of
burden tests to real sequence data, including neutral variation dramatically outnum-
bering risk variants and datasets plagued by population stratification. We also showed
that genotype imputation, a vital tool for current GWAS, can be applied in a similar
manner to increase power for burden tests of rare variants.
The explosion of data from next-generation sequencing and the unprecedented
access it provides to rare variation will provide a range of new research problems in
the field of statistical genetics, several following directly from the projects considered
here. The development of novel burden tests is a very active area of research; al-
ready our CMAT has been improved upon by methods that allow combinations of
risk and protective variants and continuous outcomes and covariates [50, 78]. How-
ever, the application of these methods to real data has been limited thus far and
performance outside of simulated data, often with idealized conditions, is not yet
known. Predictably, many of the same challenges that complicate GWAS will need
to be addresses for burden tests. Also, new unforeseen problems are likely to develop
and require solutions.
We touched on the issue of population stratification in burden tests in the second
chapter. Although the example we provided was somewhat extreme, it demonstrated
the significant problem that stratification can cause in burden tests. We showed
that stratification can be controlled for if population of origin is known, but in prac-
tice, this will need to be inferred from the data. It is not immediately clear that
existing methods to control for stratification in single marker GWAS [15, 57] will
be sufficient for burden tests. Stratification in single marker tests is the result of
differences in allele frequencies at individual markers between populations. Exist-
ing correction methods use the single-site allele frequency differences from across the
genome to assess stratification in the dataset and apply a global correction to all
tests. In contrast, stratification in burden tests is caused by differential sampling of
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cases and controls from populations containing different proportions of rare varia-
tion. Already, data from the 1000 Genomes Project suggests substantial rare variant
diversity between populations, highlighting the serious risk for stratification in bur-
den tests [18]. Patterns of rare variation can differ between populations for a variety
of reasons unrelated to the phenotype of interest. Differences in population history
including expansion, bottlenecks and migration can influence rare variant diversity
on a genome-wide level. Alternatively, selective pressures that regulate rare variant
distributions can differ between populations and act in a more localized gene-based
level. Further, the cumulative nature of burden tests implies that subtle differences
at single sites can be magnified when pooled together. The combination of these
factors may render correction methods based on genome-wide patterns of single site
differences insufficient for burden tests. Moreover, existing methods rely on extract-
ing information on diversity from common variants and may not adequately reflect
diversity at the rare variant level. New correction methods designed specifically for
burden tests will be required to account for the multiple sources of confounding de-
scribed here. It is possible that the burden statistic for each gene will need to be
individually corrected using information from both genome-wide and gene-level rare
variant distributions.
Another foreseeable challenge for rare variant association studies will be deter-
mining the effect size of genes identified by burden tests. Whole genome sequencing
will allow burden tests for the more than 20,000 genes in the human genome and
correction for multiple testing will open the door for a Winner’s Curse effect on esti-
mates of effect sizes for rare variants. A natural effect quantity to report is the risk
explained by total variation at the locus. Extending existing analytical methods to
estimate locus-effect may be difficult due to the complicated nature in which many
burden tests combine information across sites. Further, burden test statistics can be
composed of causative, protective and neutral variants creating a complex mix of ge-
netic effects. Our ascertainment-correction method described in the first chapter may
be a useful tool to handle the challenge of estimating effect size from burden tests.
The partial likelihood MCMC does not require that the effect estimate correspond to
the burden test statistic used to declare association. This is important because the
statistic used to summarize rare variant burden will almost certainly not be indicative
of effect size.
Finally, we examined the role that new sequencing technology can play in im-
proving the existing tool of imputation. We observed that custom reference panels
made directly from the study population of interest will be valuable for improving
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imputation, especially for rare variants. However, we also noted that under certain
conditions the large public reference panels will provide similar and even improved
accuracy compared to that of smaller custom panels. In the chapter, we did not
explicitly consider imputation in the setting of disease-gene mapping and perhaps
underrated the major advantage custom reference panels can provide. We briefly
mentioned in the discussion of that chapter that custom reference panels allow vari-
ants unique to the study sample to be observed and imputed. In our coalescent model
these were population-specific variants. However, if the study sample contains indi-
viduals ascertained for a specific phenotype, the unique variants in a custom panel
may include novel risk variants that could not be directly analyzed if the study sample
were imputed using a public reference panel. This is particularly important because
novel rare variants may not be tagged well enough by the public panels to enable
powerful linkage disequilibrium mapping. Thus, the benefit of the custom reference
panel may go beyond simply improving imputation accuracy to also allowing analysis
of novel risk variants that would otherwise be missed.
Several interesting questions can be posed for the design of custom reference pan-
els in a case-control setting, including strategies for choosing which individuals from
the study sample to sequence for the reference panel. For example, in our CMAT
simulations we assumed custom reference panels of equal numbers of cases and con-
trols to match the balanced design of the larger sample. An alternative strategy is to
sequence a larger fraction of cases to enrich the custom reference panel for risk vari-
ants and potentially increase association testing power. However, a potential pitfall of
this strategy is that variants appearing in the reference panel at dramatically different
frequencies than in the population are prone to severe imputation error (unpublished
data) that could bias association test results. A more thorough analysis of reference
panel design in a gene-mapping setting would help to reveal optimal strategies for
designing imputation-based analyses.
Despite the best efforts of this dissertation, it is clear that numerous challenges
remain. The tools developed here are only a small step toward the complete under-
standing of the genetics of complex disease, but we anticipate that this work will be
built upon and lead to further advances in the field of human statistical genetics.
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